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ABSTRACT 
 
  
 Telomere length has been shown to be a critical determinant of T cell replicative 
capacity and in vivo persistence in humans. We evaluated telomere lengths in virus-
specific T cells to understand how they may both shape and be changed by the 
maintenance of memory T cells during a subsequent virus re-infection or reactivation. 
We used longitudinal peripheral blood samples from healthy donors and samples from a 
long-term HCV clinical interferon therapy trial to test our hypotheses. 
 To assess T cell telomere lengths, I developed novel modifications to the flow 
cytometry fluorescence in situ hybridization (flowFISH) assay. These flowFISH 
modifications were necessary to enable quantification of telomere length in activated, 
proliferating T cells. Adoption of a fixation-permeabilization protocol with RNA 
nuclease treatment prior to telomere probe hybridization were required to produce 
telomere length estimates that were consistent with a conventional telomere restriction 
fragment length Southern blot assay. 
 We hypothesized that exposure to a non-recurring, acute virus infection would 
produce memory T cells with longer telomeres than those specific for recurring or 
reactivating virus infections. We used two acute viruses, vaccinia virus (VACV) and 
influenza A virus (IAV) and two latent-reactivating herpesviruses, cytomegalovirus 
(CMV) and varicella zoster virus (VZV) for these studies. Combining a proliferation 
assay with flowFISH, I found telomeres in VACV-specific CD4+ T cells were longer than 
those specific for the recurring exposure IAV; data which support my hypothesis. 
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Counter to my hypothesis, CMV-specific CD4+ T cells had longer telomeres than IAV-
specific CD4+ T cells.  
 We assessed virus-specific CD4+ T cell telomere length in five donors over a 
period of 8-10 years which allowed us to develop a linear model of average virus-specific 
telomere length changes. These studies also found evidence of long telomere, virus-
specific CD45RA+ T cell populations whose depletion may precede an increased 
susceptibility to latent virus reactivation. 
 I tested the hypothesis that type I interferon therapy would accelerate T cell 
telomere loss using PBMC samples from a cohort of chronic hepatitis C virus patients 
who either did or did not receive an extended course of treatment with interferon-alpha. 
Accelerated telomere losses occurred in naïve T cells in the interferon therapy group and 
were concentrated in the first half of 48 months of interferon therapy. Steady 
accumulation of CD57+ memory T cells in the control group, but not the therapy group, 
suggested that interferon also accelerated memory turnover.  
 Based on our data, I present proposed models of memory T cell maintenance and 
impacts of T cell telomere length loss as we age.  
vii 
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CHAPTER I 
 
INTRODUCTION 
 
A. Biology of peripheral T lymphocytes 
 CD4+ and CD8+ T cells have many overlapping, but also distinctly different and 
indispensable functional roles in the control of viral infections (1). However, both share 
the common characteristic of providing long-lived adaptive immunity for the host (2, 3). 
The establishment of stable pools of memory CD4+ and CD8+ T cells, able to recognize a 
specific pathogen, allows for a faster response on future pathogen-specific re-encounters. 
Thus antigen-experienced memory T cells spare the host the serious delay and 
consequences of mounting a new response with each re-infection or re-exposure. In order 
to carry out their functions, limited numbers of naïve T cells (for a primary response) or 
memory T cells (for a secondary response) must rapidly proliferate under settings of T 
cell receptor (TCR) mediated activation in a race for survival against infection. 
 
 i. Building the T cell repertoire 
 The T cell compartment is built and continuously replenished by new, naïve T cell 
production from the thymus starting before birth and continuing well into adulthood (4, 
5). The repertoire of naïve T cells contains a vast diversity in TCR sequence, allowing for 
high probability that some naïve T cells will exist to recognize any foreign epitope 
originating from an infecting virus or microbe (6). Naive T cells lack critical immediate 
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effector functions and have a homing phenotype that keeps them recirculating though 
lymph nodes to enable recognition of pathogen epitopes presented on lymph node-
resident professional antigen presenting cells (APCs) (7). When first activated, naïve T 
cells must rapidly replicate and produce growth factors, such as IL-2. It is not the naïve T 
cell, but the multitude of clonally expanded daughter cells that carry the immune 
response forward and become armed with effector functions as they pass though the cell 
cycle with some eventually become the antigen-experienced memory T cells (8). In this 
regard, proliferation serves two critical roles -- amplification of numbers and continued 
differentiation of T cell effector functions. Understanding what influences the output of 
memory T cells thus necessitates understanding the input: naïve T cells, the 
“compartment” in which they reside, and how they are maintained (Figure 1.1). 
 
 ii. Thymic involution as we age 
 Our thymus undergoes a process after puberty that is termed involution, which 
steadily reduces the number of recent thymic emigrants (RTEs) in the naïve T cell 
compartment. Involution is the gradual shrinking and structural architecture change of the 
thymus as we age, thought largely due to accelerating senescence of thymic epithelial 
cells and loss of the cytokines they produce (5). A consequence of age-related thymic 
involution is an increasing reliance on homeostatic maintenance of the existing naïve T 
cell compartment (9, 10). 
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Figure 1.1  The dynamics of peripheral T cells 
Naïve T cells emigrate from the thymus with an undifferentiated molecular phenotype, 
i.e. other than a high capacity to proliferate they lack most immediate effector functions 
such as interferon secretion or cytolytic killing capacity. Naive T cell numbers are 
maintained by the inflow of recent thymic emigrants (RTEs) and by slow homeostatic 
proliferation. Naïve T cell homeostatic proliferation is controlled by limiting levels of 
growth and survival cytokines, thus regulating total numbers. T cell loss from the naïve 
compartment can occur as a result of bystander death or by recruitment to become 
effectors or memory T cells. In the context of viral infections or immunization with viral 
antigen, professional antigen presenting cells (APC) provide signals for naïve T cell 
recruitment, activation, and expansion. Effector T cells generated during activation may 
be short-lived and undergo activation-induced cell death (AICD) or become effector 
memory cells for homeostatic maintenance within the memory compartment by survival 
cytokines. During memory responses, professional APCs can re-activate memory cells 
and drive further expansions. Age-related thymic involution results in a steady decline of 
RTEs. Homeostatic proliferation within the memory T cell compartment proceeds 5-10 
times faster than in the naïve T cell compartment. Essential questions (?) exist in 
understanding “how” and “which” activated, reactivated, or effector T cells “decide” to 
become longer-lived memory T cells.  
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 iii. Memory T cells  
 
 a. Immediate effector responses of memory T cells 
 Memory T cells are capable of varying levels of immediate effector functions 
since they have already undergone a program of activation-induced expansion (11, 12). 
CD8+ T cells act primarily through inducing programmed death of infected cells; a 
response termed a type 1 response (1). CD8+ T cells deliver direct and indirect cytotoxic 
and antiviral signals to infected cells, while releasing signals to recruit other effector cells 
to these tissues.  
 CD4+ T cells have been similarly described with all the helper type 1 (Th1) 
effector functions of CD8+ T cells, but also are capable of other “helper” functions to 
guide, control, and limit immune responses of innate and adaptive immunity. CD4+ T 
cells have been termed the master regulators of the immune system where they “license” 
and regulate many facets of activation in both adaptive and innate immunity. CD4+ T 
cells are essential in the development of long-lived memory CD8+ T cells with cytotoxic 
capacity and to B cells in generating long-lived antibody-secreting cells, the classically 
described Th1 and Th2 CD4+ T cell responses, respectively (13-15). More recently, this 
B cell antibody supporting role has been expanded to include CD4+ T cell helper 
functions necessary in the lymph node follicle termed a T follicular helper (Tfh) response 
(16).  
 Human memory CD4+ T cells have been divided into two subsets of memory T 
cells with distinct homing potentials and effector functions based on the L-selectin 
receptor expression, CD62L (17). More differentiated, Th1 effector memory T cells lack 
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CD62L; conversely CD62L+ expression is associated with a less differentiated central 
memory T cell phenotype (18, 19). In this regard, human activated CD62L+ CD4+ 
memory T cells mainly produce IL-4 and IL-5 associated with supporting B cell 
responses, whereas CD62L- CD4+ T cells produce interferon-gamma, the signature Th1 
cytokine (13, 16, 20). Importantly, formation of CD62L- effector memory CD4+ T cells 
has been reported necessary for recovery of immune-suppressed transplant recipients 
from a cytomegalovirus (CMV) reactivation (21). The essential anti-viral effect of 
CD62L downregulation from T cells is also seen in experimental mice models of 
influenza virus infection (22). Furthermore, acquisition of tumor infiltrating cytolytic 
activity in T cells is associated with the shedding of CD62L from the T cell surface (23, 
24). In mice and in humans, in vivo IL-2–derived signals promote the downregulation of 
CD62L and formation of the effector memory CD4+ and CD8+ T cell population (24, 25). 
Taken together, these data support the model that differentiation of T cells with more 
cytotoxic Th1, effector-like, CD62L- properties are likely critical aspects in the control of 
viral infections. 
 Small numbers of virus-specific T cell clones must rapidly proliferate over several 
days to produce a large number of activated, virus-specific T cells to carry-out the anti-
viral effector functions. After the pathogenic microbes are eliminated, T cell numbers 
typically contract to only a small percentage of their maximal size through apoptosis; 
only a limited number of antigen-experienced cells remain to form the memory pool. 
How newly activated T cells become memory T cells is controversial and appears to 
depend on many factors (26). 
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  b. Rapid recall of memory T cells 
 Differentiated T cells undergo multiple cycles of DNA replication where T cells 
can progressively alter their chromatin and gain functions as they cycle (8, 27-29). Naive 
and less differentiated memory T cells express a range of cell surface co-stimulatory 
molecules, most notably CD28 and CD27, which provide signaling from stimulated 
APCs that enhances cellular metabolic functions during activation-induced proliferation. 
Highly differentiated T cells are often characterized by the loss of one or both of these 
molecules (30).  
 The proliferative capacity is quite low or even non-existent in highly 
differentiated T cells, especially those with high cytotoxic capacity (19, 31). Accordingly, 
in order for quiescent memory T cells to retain robust proliferative capacity in response to 
TCR signaling, the maintenance of memory T cells with a less than a fully differentiated 
state would appear to be a necessary prerequisite. How T cells of the same clonal origin 
decide different fates on the path to division and differentiation, with some as 
differentiated effectors and others as long-lived memory cells maintaining replicative 
capacity, is a central and critical question in T lymphocyte research. 
 
  c. Reactivation of memory T cell responses 
 Re-vaccination or boosting is a common vaccination strategy to induce robust 
immunity. Many vaccines, particularly those with inactivated or highly attenuated 
pathogens, produce weak responses with a single inoculation. Most vaccines seek to 
attain high levels of virus neutralizing antibody levels via B cells to provide protective 
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immunity. However, a successful, high affinity antibody response is still dependent on T 
cell help to “license” the obligate B cell affinity maturation and isotype switching 
reactions (16, 32). Thus antigens from the vaccine preparations must simultaneously 
stimulate CD4+ T cells to assist the B cell reactions.  
  
  d. Homeostasis in the control of peripheral T cell compartments 
 A key feature of both naïve and memory T cell compartments is their relatively 
stable size over periods of many years (33). This overall homeostasis, or stability, occurs 
despite periodic infections inducing activation-driven clonal expansions to specific 
pathogens (34, 35), cytokine signaling from severe infections inducing infrequent 
episodes of lymphopenia, as well as thymic involution reducing the supply of RTEs (9, 
36). The stable size of T cell compartments has been shown in mouse models to be 
dependent on the maintenance of a stable cytokine environment, notably IL-7 levels (9, 
37). Effector T cells are also dependent to varying degrees on IL-15 and/or IL-21 for 
survival and growth (9). While IL-2 provides a critical growth and differentiation signal 
to effector T cells undergoing activation-induced expansion, its role in homeostasis 
appears largely confined to regulating the size of CD4+ regulatory T cell numbers (38, 
39). Thus the general picture is one of heterogeneous T cell compartments sustained and 
maintained by a milieu of soluble cytokines. 
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B. Model Viral Infections of Humans  
 Some virus infections are acute – they are resolved quickly within a week or two 
and the pathogen is no longer detectable in the host, whereas other viral infections lead to 
persistent infections with a prolonged pathogen and antigenic presence providing chronic 
T cell stimulation (40). Finally, there are the latent-reactivating herpesviruses. In their 
natural host reservoirs, herpesviruses initially infect in an acute manner and then play a 
highly evolved game of “hide and seek” with the immune system after the acute phase 
resolves (41). How each of these virus-host models produce the persistence of virus-
specific memory T cells likely relies on common mechanisms of T cell biology during 
induction. However each “model” may then play out in a different manner with time and 
re-exposure of the immune system to that specific or similar pathogen(s). 
 
i. Acute virus infections 
 Acute virus infections are those which are eliminated by the immune response, 
usually within a period of several weeks or less. In this context, seasonal influenza A 
virus (IAV) is considered an acute virus, one that healthy individuals are able to clear and 
which induces long-lived immunity.  However, due to a process termed “antigenic drift,” 
various IAV surface proteins slowly change each year, resulting in seasonal outbreaks of 
IAV (42). Thus, we are typically re-exposed to closely related IAV variants each season 
in a recurring pattern (43).  
 Existing high affinity antibodies would neutralize any virus that made its way past 
physical surface barriers, and then may present that viral antigen to memory T cells by 
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APCs and B cells. This would provide periodic TCR stimulation of T cells during the flu 
season even in the absence of productive infection. Overall, the effect of these periodic 
re-exposures, both infectious virus and vaccine antigens, may be such that virus-specific 
memory T cells become activated and expand, without a need for recruitment of new T 
cells to memory. Understanding how these recurring antigenic encounters may affect 
maintenance of T cell memory to IAV may be crucial to elucidating what factors may 
limit successful seasonal influenza immunizations. 
 Live vaccinia virus (VACV) is another acute infecting virus; it was used as the 
immunizing agent to eradicate smallpox. Individuals born before 1970 were routinely 
vaccinated with live VACV via skin scarification (44, 45). Since that time, VACV 
immunizations have been limited to medical, laboratory, and military personnel (46).  Re-
exposure of the immune system to VACV is generally assumed to be non-existent outside 
of known vaccinations. Immunization with VACV has been described as inducing life-
long immunity through the production of virus-specific antibodies and memory T cells  
(44, 47).  
 
 ii. Chronic viral infections and exhaustion  
 Some viruses, such as human immunodeficiency virus (HIV), induce a state of 
chronic infection. HIV primarily infects CD4+ T cells and causes a persistent viremia 
leading eventually to severe immune deficiency (48, 49). Hepatitis B and C viruses (HBV 
and HCV) initiate a chronic infection in the liver with sustained viremia, which can 
produce sustained liver damage and cirrhosis (50-53). Type I interferon is the accepted 
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clinical therapy for chronic HCV infection, and is also used for some patients with 
chronic HBV infection (54, 55). Additionally, elevated production of circulating type I 
interferons by innate cells in response to chronic viremia maintains the immune system in 
a continuous non-specific activated state (56, 57). This chronic immune activation in HIV 
infection by interferon is suspected as one of the causes leading to the depletion of T cells 
during the descent to immune deficiency (58, 59). Related to this effect, type I interferons 
have been shown in mice to produce bystander effects of apoptosis and/or reduced 
proliferative responses to TCR-signaled activation in T cells (60, 61). 
 These chronic virus infections have competing effects on the formation of specific 
T cell memory. Although HIV, HBV, and HCV initially drive a potent acute phase 
immune response, in the chronic phase long-term T cell memory fails to be either fully 
established and maintained by unclear mechanisms (62). This failure to maintain the T 
cell response has been termed clonal exhaustion, as the replicative capacity and effector 
functions of virus specific T cells diminishes with time (becomes exhausted) as the 
infection continues. With clonal exhaustion, virus-specific T cell numbers eventually fall 
to near undetectable levels.  
 
 iii. Latent virus infections and periodic reactivation 
 Herpesvirus infections, while having an acute primary phase with large scale 
virion production which seeds the virus throughout the body, eventually establish a life-
long infection in specific target cells. Latency occurs after the immune response 
successfully eliminates lytically infected cells (those producing virus). Viral latency is a 
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state in which the virus hides from the host immune system by maintaining its viral DNA 
genome in the cell nucleus but expressing few if any viral epitopes on the cell surface 
(63-65). Two very common latent-reactivating herpesviruses differ in their host 
interactions, such as the frequency of reactivation and sites of latency. Cytomegalovirus 
(CMV) is thought to establish latency in a wide range of tissues and cell types, especially 
ubiquitously dispersed myeloid lineage innate immune cells, and to reactivate frequently 
(41). Varicella zoster virus (VZV), the virus of both chickenpox and shingles, establishes 
latency in ganglionic neurons and likely reactivates infrequently (66-68). Nevertheless, 
both viruses require life-long T cell-mediated immunity for their control (41, 69). 
Memory T cells reactive to these two herpesviruses are readily detectable in seropositive 
individuals (70). CMV is thought to form the basis of T cell memory clonal expansions 
seen in aging populations, where high frequencies of CD8+ CMV-reactive T cells are 
common (66, 71). The basis for this T cell memory “inflation” is still poorly understood, 
but may relate to the frequency of reactivation of CMV and thus restimulation of T cell 
proliferation (41). 
 
C. Telomere biology 
 Cellular DNA damage response (DDR) machinery must repair chromosome 
strand breaks that occur due to damaged nucleotides, replication fork stalls, or cross 
linked DNA. In doing so, the DDR machinery efficiently recognizes and ligates two 
DNA strands in an end-joining reaction (72, 73). In contrast, in order to maintain a stable 
genome through mitosis, the true termini of the chromosomes must not be fused. 
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Accordingly, cells have evolved a unique end structure - the telomere. Through complex 
mechanisms, functional telomeres prevent the end-joining DDR reactions between 
chromosomes. Telomeres are repetitive DNA sequences, consisting of hundreds to 
thousands of double-stranded repeats, found at both ends of every chromosome (74).  
 The normal diploid (2n) human cell has 46 chromosomes, and thus 92 telomeres. 
For every molecular solution, though, new complications arise – each telomere must be 
maintained during DNA replication. Telomere-associated proteins, termed the shelterin 
complex, recognize the unique six base pair (bp) telomere repeat sequence, 5’-TTAGGG-
3’, with high specificity and affinity. In addition to the long double-stranded repeats, the 
very end of the telomere terminates in a 3’ G-rich overhang of up to several hundred 
bases formed by an unknown nucleolytic processing reaction (Figure 1.2.A) (74, 75). 
Shelterin complexes use poorly understood conformational changes to protect and 
safeguard the telomeres and their single-strand 3’ DNA overhang from being recognized 
as DNA damage by the DDR pathways. When a telomere becomes exposed, this has been 
described as an “uncapped” state due to an altered shelterin-telomere configuration (76). 
Thus, if the telomere sequence reaches a critically short length and shelterin is unable to 
“re-cap” the telomere, a sustained DDR signaling cascade results in cell cycle arrest, i.e., 
a normal cell with too short, uncapped telomeres can no longer divide (Figure 1.2.B). 
 
 i. Telomere length encodes replicative potential 
 A normal cell’s replicative potential has been linked to a combination of its 
telomere length (TL) and the ability to maintain that length, usually through expression of 
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the telomerase enzyme  (77-79). Steady telomere shortening during cellular division, 
termed erosion, with the imposition of cell cycle arrest when telomeres get too short, 
protects chromosomal integrity and forms a barrier to unlimited growth of normal human 
cells (77). Telomere erosion and subsequent cell cycle arrest by critically short telomeres 
provided the molecular explanation to the so-called Hayflick limit observed almost 50 
years ago -- the replicative limit observed when fibroblasts, continually grown in culture, 
slow their replication and eventually stop cycling, unable to further divide (78, 80). 
Telomere erosion occurs due to both the end-replication problem and the nucleolytic 
processing of the telomere ends.  Telomere erosion during chromosomal replication 
typically results in 50-120 bp of telomere loss per cell cycle. Thus telomere erosion in 
human cells during replication is effectively a molecular cell cycle counting device which 
imposes limits on a normal cell’s replicative capacity in the absence of some mechanism 
to reverse telomere erosion. 
 
ii. Telomerase assists in telomere maintenance 
 Telomerase is a unique reverse transcriptase enzyme that elongates the G-rich 3’ 
end of telomeres to assist in telomere maintenance during replication (Figure 1.2.C) (79, 
81-83). The enzymatic action of telomerase on telomeres has been shown to be dose-
dependent; high levels of telomerase during replication have been shown to arrest 
telomere erosion during rapid cell cycling and at very high levels telomerase can produce 
telomere elongation. B and T lymphocytes are among the few human somatic cells that  
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Figure 1.2  Telomeres provide a unique structure to protect chromosomes 
 
(A) Every chromosome end contains thousands of double strand repeats of the 5-
TTAGGG-3’ sequence. The G-rich single-strand overhang is nucleolytically formed by 
end-processing reactions. (B) Multiple shelterin protein complexes (not shown for 
clarity) recognize the telomere sequence and catalyze the folding reaction to form a 
capped telomere which suppresses the DNA Damage Response (DDR) signal. Telomeres 
with insufficient length are not able to be capped by shelterin. Uncapped telomeres 
activate the DDR which precipitates cell cycle arrest. (C) Telomerase, if expressed, 
elongates the G-rich strand during replication. Unknown C-strand fill-in reactions 
complete the telomere maintenance and elongation process during late S-phase and G2-
phase allowing the telomere to regain a capped state. 
  
15 
are capable of expressing significant amounts of telomerase during activation-induced 
proliferation. During clonal expansion, telomerase activity and maintenance of telomeres  
are crucial to a sustained CD4+ and CD8+ T cell memory response (79, 81, 84).  
However, telomerase activity in activated T cells has been shown to be dependent on 
many factors including how many times a T cell has undergone activation-induced 
proliferation and the cytokine signaling environment (82, 85, 86).  
 
  a. Telomerase inhibition  
 Type I interferons (IFN), in addition to anti-viral and anti-proliferative effects, 
inhibit expression and activity of telomerase (86). IFN also commonly causes 
lymphopenia (87), which is a stimulus for homeostatic proliferation (9). How these 
competing phenomena of telomerase inhibition, anti-proliferative effects, and stimulated 
homeostatic proliferation may affect naïve and memory T cell telomere lengths is 
unclear. In addition to cytokines such as interferons, repeated T cell activation-induced 
proliferation also leads to repression of telomerase expression and activity in human T 
cells. After 4 or more rounds of in vitro TCR-signaled activation, T cells have been 
shown to have mostly lost telomerase activity, with a gradual diminishment of telomerase 
activity occurring at each sequential activation (79, 84, 85).  
   
  b. T cell telomere kinetics 
 TL in naïve T cells in adults, typically measured as an average or mean TL, 
ranges from 6000-11000 base-pairs. Mean TL in memory T cells is typically 1200-1500 
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Figure 1.3  T cell telomere lengths decline with age 
 
Graph depicts age-dependent decline in peripheral blood in naïve and memory T cell 
telomere lengths adapted from (88).   
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base pairs shorter than in naïve T cells (Figure 1.3) (88, 89). T cell differentiation status, 
seen as a continuum of loss of co-stimulatory markers such as CD27 and CD28, loss of 
effector functions, cell cycle withdrawal, and expression of higher levels of inhibitory 
markers, highly correlates to increasing loss of TL (30, 81, 83). In vivo isotopic labeling 
studies have shown that memory T cells in the peripheral blood turn over much more 
rapidly than naïve T cells (10, 90, 91). Further, T cells undergoing in vivo homeostatic 
proliferation do not express the high levels of telomerase believed necessary to arrest the 
typical 50-120 bases of telomere loss per division (79, 85, 92). Thus, given the 
established memory T cell TL in adults, these reported turnover rates and the lack of 
telomerase during homeostatic turnover would theoretically lead to cellular senescence of 
memory T cells and loss of proliferative capacity within a decade. 
 
iii. Telomere length maintenance affects in vivo T cell persistence 
 There are differences in the maintenance of CD4+ and CD8+ T cell memory. 
Despite similarly robust CD8+ T cell responses during a primary infection, CD4+ memory 
T cell responses are generally more durable than CD8+ memory T cell responses (45, 47, 
93, 94). Differing abilities of CD4+ and CD8+ T cells to up-regulate telomerase and limit 
telomere erosion during activation-induced proliferation have been proposed to account 
for these differences (95). Further, TL has been shown to be a critical determinant of T 
cell replicative capacity and in vivo T cell persistence in clinical trials. Adoptive transfer 
of CD8+ tumor-infiltrating lymphocytes with long telomeres into melanoma cancer 
patients correlates with better in vivo T cell persistence and proliferation, while excessive 
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in vitro expansion leading to shortened telomeres correlates with poor in vivo persistence 
(96, 97).  
 iv. Differences between T cell senescence and exhaustion 
 Loss of replicative capacity is seen in the phenomenon of clonal exhaustion, as 
discussed above. However, senescence of T cells due to telomeres reaching critically 
short lengths appears to be molecularly distinct from clonal exhaustion. It has been 
shown that clonally exhausted T cells in certain chronic infections can be induced to re-
enter the cell cycle if inhibitory signals such as programmed death-1 (PD-1) or IL-10 are 
blocked or removed at specific, critical times in the immune response (98-103). However, 
telomere-dependent senescence is irreversible in normal T cells, unless telomerase 
expression is ectopically forced, for example, by the insertion of a transgene (104-106). 
Indeed, in the very elderly, where clonally expanded, poorly proliferative, CMV-reactive 
CD8+ T cells are common, their TL has been described as very short (66, 71, 107, 108). 
How telomere-dependent senescence may progress to impede the replicative capacity of 
other virus-specific memory T cells in humans is unclear, especially for T cells specific 
for acute virus infections such as IAV or VACV. 
  
D. Measurement of telomere length 
 Various molecular techniques have been devised for measuring TL. The telomere 
restriction fragment (TRF) Southern blot assay represents the oldest and most established 
assay and, as such, is the gold standard for TL measurement (109). Other TL assays also 
use DNA extraction from large numbers of cells and then apply quantitative PCR with 
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carefully designed primers to estimate TL. TRF Southern blot and PCR-based assays 
suffer from the fact that extraction of DNA from cells erases information regarding TL 
distribution at the single cell level. One technique developed 13 years ago uses 
fluorescent in situ  hybridization (FISH) of a fluorescent-labeled telomere sequence probe 
with flow cytometry to enable high speed measurement of TL of a large number of cells, 
the flowFISH assay (110). 
   
 i. FlowFISH in TL estimation and caveats in its use 
 Using flowFISH to analyze TL in peripheral blood cells requires the use of a 
DNA counterstain to ensure a 2n diploid DNA content (92 telomeres) in every measured 
cell. Thus in flowFISH TL measurement, it is crucial that TL is not estimated in cells 
captured during hybridization that were undergoing DNA synthesis (S phase) or in G2/M 
where the number of chromosomes is no longer diploid. Beyond that caveat, 
hybridization conditions (heating to 82oC in formamide) used to denature the DNA 
results in the destruction of most protein epitopes available for antibody labeling in flow 
cytometry. Thus molecules such as CD4 or CD8 must be labeled before hybridization, 
and the antibody then covalently cross-linked to prevent dissociation at the hybridization 
temperature. When pre-hybridization staining is employed, the use of heat stable 
fluorochromes (such as fluorescein or the patented Alexa dyes) is necessary. Together 
these caveats serve to limit the available phenotypic markers that can be incorporated in 
flowFISH. 
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 ii. Identifying low frequency phenotypes 
 Low-frequencies of virus-specific T cells and the limited numbers of HLA-
peptide tetramers available have restricted the study of TL mainly to CD8+ T cells 
specific for a few highly immunodominant epitopes, with more limited studies of CD4+ 
memory T cells (82, 107, 111, 112). In order to study T cell memory across a wide-range 
of individuals, other methods to evaluate virus-specific T cells are needed. Proliferation-
based assays have long been used to identify and quantitate memory T cell responses, but 
merging these with telomere length measurement and flow cytometry-based phenotyping 
has been a costly and labor intensive process usually employing cell sorting (109). 
Merging flowFISH telomere measurements at the single-cell level with phenotypic 
analysis in a proliferation assay offers the potential to overcome many of these 
limitations to offer new insight into the TL dynamics of memory T cells. 
 
 iii. Statistical parameters of TL distributions  
 Beyond an arithmetic mean TL (mTL), flow cytometry allows for determination 
and examination of the statistical parameters of distribution such as median TL and 
coefficient of variation (CV, standard deviation divided by mean). One underappreciated 
power of flowFISH in TL studies may be the elucidation of TL distributions, i.e. 
measures beyond a simple mTL. The presence of highly-skewed TL distributions could 
conceivably be a critical correlate of the maintenance of T cell memory. 
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E. Thesis objectives 
 The broad objective of this thesis was to investigate the maintenance of memory 
T cells by studying their telomere biology. This work was driven by the desire to further 
our understanding of how pathogen re-exposure and the cytokine environment may shape 
the maintenance of naïve and memory T cells. Toward that goal, I established two 
hypotheses. 
 1) Virus-specific memory T cells that proliferate in response to acute, non 
recurring infections have longer telomere lengths than T cells that proliferate in 
response to recurring or reactivating viral infections. 
 Rationale: recurring in vivo antigen presentation induces periodic antigen-specific 
memory T cell proliferation leading to their decreased telomere length. 
  
 2) Long-term exposure to type I interferons result in significant reduction in 
average telomere lengths in peripheral blood T lymphocytes. 
 Rationale: type I interferons inhibit telomerase expression in activated T cells 
thereby reducing telomere length. 
 
This work is presented in three parts: 
 Chapter III: Developing the flowFISH assay 
 Questions addressed: 
• Can flowFISH protocols be modified to discriminate between CD4+ and 
CD8+ T cells for TL estimates in naïve and memory compartments? 
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• Can flowFISH TL measurement be extended to proliferating T cells? 
• Can virus-specific T cells that proliferate in response to viral antigens be 
identified in flowFISH for TL measurements? 
 
 Experimental approach 
• Compare CD4 and CD8 staining with and without the effects of 
hybridization to discriminate these two subsets in flowFISH. 
• Evaluate flowFISH TL results in proliferating T cells with results from an 
accepted TL assay. 
• Combine a proliferation assay directly with flowFISH to identify virus-
specific T cells by their replicative response to virus. 
 
 Chapter IV: Telomere length dynamics in human memory T cells specific  
 for acute and latent viruses 
 Questions addressed: 
• Does telomere length differ in virus-specific T cells that proliferate in 
response to acute, non-recurring infections compared to acute recurring 
virus infections? 
• Do telomere length kinetics (rate of TL change) differ between acute, non-
recurring virus-specific T cells and recurring virus-specific T cells (Figure 
1.4)? 
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Experimental approach: 
• Measure TL in CD4+ and CD8+ T cells that proliferate in response to 
viruses in a cross-sectional study of healthy donors. 
• Longitudinal analysis of TL to assess kinetics of virus-specific T cells. 
 
 Chapter V: Extended interferon therapy accelerates telomere loss in  
 peripheral blood T lymphocytes 
 Question addressed: 
• Does sustained type I interferon therapy reduce telomere length in 
peripheral blood T cells? 
 
 Experimental approach: 
• Use peripheral blood samples from a long-term HCV clinical interferon 
therapy trial to measure telomere lengths in a representative cohort from 
those receiving sustained interferon and those in a control, no-therapy 
group.
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CHAPTER II 
 
MATERIALS AND METHODS 
 
A. Ethics Statement 
 Blood samples were collected and cryo-preserved from healthy donors (Chapters 
III and IV) in accordance with protocols approved by the University of Massachusetts 
Medical School Human Subjects Committee. All subjects provided written, informed 
consent to participate. 
 All subjects enrolled in the HALT-C trial (Chapter V) provided written, informed 
consent for participation under protocols approved by the institutional review boards of 
all participating study centers and which conformed to the ethical guidelines of the 1975 
Declaration of Helsinki. PBMC samples for this research came from the following 
institutions:  University of Massachusetts Medical School, Worcester, MA; University of 
Connecticut Health Center, Farmington, CT; Saint Louis University, Saint Louis, MO; 
University of Texas Southwestern Medical Center, Dallas, TX; and University of 
Southern California Health Sciences Campus, Los Angeles, CA. 
 
B. Donors and Peripheral Blood samples 
 Peripheral blood mononuclear cell (PBMC) samples for studies in Chapters 3-5 
were obtained from fresh whole blood using the protocols described below. PBMC 
samples from the HALT-C clinical trial used in Chapter 5 were provided as 
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cryogenically-preserved aliquots from SeraCare Life Sciences (Milford, MA) tissue 
repository in coordination with the HALT-C Steering Committee and the New England 
Research Institute (NERI). A description of the HALT-C patient sample cohort is 
provided below. 
 
 i. Normal donor PBMC 
 Whole blood was collected and PBMC separated using Ficoll-PaquePlus (GE 
Healthcare) or Histopaque-1077 (Sigma). PBMC samples were cryo-preserved in liquid 
nitrogen in aliquots of 107 cells/vial in 90% Fetal Calf Serum plus 10% dimethyl 
sulfoxide. All subjects had received the smallpox vaccine at least 3 months prior to blood 
collection (one donor at 3 months post-DryVax vaccination, all others > 1 year). None 
had reported a recent influenza infection. 
  
 ii. HALT-C telomere length study   
 The HALT-C trial design has been described in detail elsewhere (113). Briefly, 
enrollment criteria required all subjects to have histologically-confirmed liver fibrosis or 
cirrhosis (Ishak score ≥3). Subjects who remained viremic after 6 months of “lead-in” 
therapy with peg-IFNα plus ribavirin were then randomized either to continued 
maintenance-dose (90 μg/week) peg-IFNα for an additional 3.5 years or a monitor-only 
control group, for a total study duration of 48 months per patient (Figure 2.1). Thus the 
randomization phase consisted of these two groups, the peg-IFNα therapy group and the 
no-therapy control group. Neither subjects nor clinicians were blinded to treatment  
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Figure 2.1  Design of the HALT-C trial and timing of PBMC available for telomere 
length analysis  
 
Chronic hepatitis-C virus patients provided blood samples at baseline screening (S00). 
Upon enrollment, subjects received 24 weeks of lead-in peg-IFNα plus ribavirin therapy. 
Those who remained viremic were randomized into one of two arms -- no-therapy 
monitoring-only (control group), or continuous peg-IFNα therapy at a reduced main-
tenance dose for an additional 3½ years. PBMC for these TL studies came from S00, 
month 21 (M21), and month 45 (M45).  
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assignment during randomization. PBMC samples for telomere length analysis came 
from a representative subset of the HALT-C cohort consisting of 29 patients who 
successfully completed the 48 month randomization phase. PBMC were studied from 
three time points within the trial:  baseline (S00), month 21 (M21), and month 45 (M45).  
 For this telomere length study, subjects from each randomization group, peg-
IFNα treatment and control, were selected as matched-pairs, based on age, gender, and 
Ishak fibrosis score. Subjects for the peg-IFNα therapy group were selected for high 
compliance (>80%). For TL analysis, we were blinded to treatment group assignment, 
subject characteristics, and chronological order for each subject until after the completed 
TL data set was returned to the HALT-C Data Coordinating Center. Subject data (Table 
2.1) included: age at enrollment and PBMC collections, gender, race, body mass index 
(BMI) at enrollment, estimated duration of HCV infection, serum alanine amino 
transferase (ALT) levels, serum HCV RNA levels, and Ishak fibrosis score (114-116). 
 
C. BrdU Proliferation Assay 
 Thawed PBMC were washed, counted, and plated at 2.75x105 cells per well in 96-
well plates in complete media with a final volume of 200 μL per well. Complete media 
consisted of RPMI-1640 (Gibco-Invitrogen), 10% human AB serum (CellgroMediatech), 
penicillin-streptomycin, and L-glutamine. Antigens added to wells were gamma-
inactivated IAV (A/H3N2/Texas/77/1), gamma-inactivated human CMV (strain AD- 
169), or gamma-inactivated VZV (strain VZ-10) (all from Microbix Biosystems Inc., 
Ontario Canada), at a final dilution of 1:100. For VACV stimulation, live virus (strain:
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NYCBH) was used at an moi = 0.2. Included in all experiments was a medium-only 
(negative) control to assess background proliferation. On day four of culture, bromo-
deoxyuridine (BrdU, BD BioSciences) in complete media was added at a final 
concentration of 2 μM to all wells. All cultures were harvested on day 7 unless specified 
otherwise. All virus-stimulated samples from the same subject were analyzed in the same 
experiment to minimize potential sources of variation. For surface phenotype evaluation, 
2x105 cells were processed and analyzed as described below. FlowFISH telomere length 
analysis was performed on the remainder, typically 2.0-2.5 x 106 cells, as described 
below. A positive T cell response to virus was defined as proliferation (percent BrdU+ 
cells) of 5-fold over the media background proliferation. 
 
D. RNA nuclease treatment and snRNA 7SK FlowFISH analysis 
 A small, nuclear localized RNA, 7SK, was chosen to test and optimize RNA 
nuclease treatments in human PBMC samples for peptide nucleic acid (PNA) probe 
florescent studies in flowFISH. The 7SK target sequence used has been published by 
others in fluorescent in situ hybridization studies (117, 118). Peripheral blood 
mononuclear cell samples were fixed in 4% formaldehyde and 0.05% saponin for 25 
minutes at 4oC, and then washed twice with 2 mL lithium-based saline with 0.05% 
saponin to remove fixative. All samples were incubated in lithium-based RNA nuclease 
buffer plus 0.05% saponin, with RNA nuclease concentration and times as indicated. All 
incubations were performed at 37oC in sealed tubes with occasional vortexing to re-
suspend the cells. The PNA probe sequence for snRNA 7SK hybridization was FAM-
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OO-CCTTGAGAGCTTGTTTGG-EE (Panagene, South Korea) and the probe was used 
at a concentration of 0.7 μg/mL in 70% formamide hybridization buffer at 82oC. 7SK 
probe hybridizations were conducted in triplicate along with no-probe controls using 
flowFISH hybridization conditions and cytometry settings described in the next section. 
 
E. FlowFISH telomere length assay on direct ex vivo PBMC samples  
 Telomere length (TL) was measured in PBMC samples using a modified 
flowFISH assay (119). 4x106 PBMC from each sample were stained with anti-hCD4 and 
anti-hCD8 (eBiosciences, San Diego, CA) as described in Table 2.2, treated with 1mM 
suberic acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt crosslinker, and then 
quenched with 50 mM Tris-HCl. Cells were fixed in 4% formaldehyde and 0.05% 
saponin for 25 minutes at 4oC, and then washed twice with 2 mL lithium-based saline 
with 0.05% saponin. All samples were incubated in lithium-based RNA nuclease buffer 
plus 0.05% saponin with 2 μL RNase One (Promega, Madison, WI) for two hours. 
Samples were then divided to three probe (+) tubes and one probe (-) tube for 
hybridization in 70% formamide, 150 mM lithium-chloride buffer at 82oC for 12 minutes. 
Probe (+) tubes contained Cy5-OO-(CCCTAA)3-EE peptide nucleic acid probe at 0.5 
μg/mL. After overnight cooling, samples were washed twice in 70% formamide buffer. 
Samples are washed once with 2 mL PBS, stained with anti-hCD45RA antibody and anti-
CD57 as described in Table 2.2, resuspended in PBS-BSA containing 0.1 μg/mL 4′,6-
diamidino-2-phenylindole, dihydrochloride (DAPI), and transferred to analysis tubes. 
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F. FlowFISH telomere length assay on cultured PBMC 
 TL was measured in cultured PBMC subsets using the basic flowFISH assay as 
described above with the following modifications. For BrdU proliferation assays, 
multiple wells for each culture condition (typically from 14 to 16 wells for each condition 
from 96-well plates) were pooled. 2.0 to 2.5 x106 PBMC from each harvested sample 
were stained at 4oC with anti-hCD4 and anti-hCD8 (eBiosciences, San Diego, CA) as 
described in Table 2.2., and washed in cold phosphate-buffered saline (PBS) containing 
0.1% bovine serum albumin (BSA). Subsequent cross-linking of antibodies, fixation-
permeabilization, washing, RNA nuclease treatment, and hybridizations of samples were 
carried out as described above in section 3.E. After overnight cooling in the dark, 
samples were washed twice with 1 mL of 70% formamide, 0.1% BSA, 150 mM sodium 
chloride wash buffer, then once with 1 mL 1X commercial permeabilization-wash buffer 
(perm wash, BD Biosciences). Finally, samples were stained with anti-CD45RA and anti-
BrdU antibodies (BD Biosciences) as described in Table 2.2, for 1 hour at room 
temperature in perm wash buffer. Samples were washed twice and resuspended in PBS-
BSA containing 0.1 μg/mL of DAPI and transferred to flow cytometry analysis tubes. 
 
G. Flow cytometry for flowFISH 
 All samples were analyzed on a FACS-Aria flow cytometer.  DAPI-based DNA 
content and PNA hybridized probe signals were collected with linear amplification. 
Calibration beads were run prior to every experiment to configure and verify cytometer 
baseline alignment and performance. For Chapters 3 and 4, a minimum of 30,000 lymph-
33 
gated events per tube were collected for offline analysis. Each sample probe (-) tube 
mean fluorescence intensity (MFI) was subtracted from the MFI of the matching probe 
(+) tube to obtain a specific MFI. For Chapter 5, a minimum of 20,000 lymphocyte-gated 
events were collected for every tube. Each sample probe (-) tube mean fluorescence 
intensity (MFI) was subtracted from the average MFI of the matching three probe (+) 
tubes to obtain a specific MFI. Linear calibration beads (RLP-30-5, Spherotech) were run 
at the end of all experiments for conversion of experimental mean fluorescence intensities 
(MFIs) to an inter-experimental standard measure of molecules of equivalent 
fluorescence (MESF). Mean telomere length (mTL) estimates are made in units of 
MESF. Using the RLP-30-5 linear calibration bead-derived linear best-fit equation, linear 
performance in the Cy5 telomere probe channel was verified (r2>0.99) in all analysis 
runs. Cytometry file analysis was performed with Flowjo v7.2.5 (Treestar, Ashland, OR).  
  A healthy donor PBMC sample analyzed in triplicate in four separate flowFISH 
analyses provided inter-assay and intra-assay coefficients of variation (CV). Inter-assay 
CV for all CD4+ and all CD8+ T cells were 7.4% and 6.6% respectively. Intra-assay CV 
for all CD4+ and all CD8+ T cells were 1.1% and 1.3% respectively. For in vitro cultured 
PBMC, samples from each subject’s three time points were run in the same assay to 
minimize the effect of inter-assay variation. 

35 
H. Telomere restriction fragment (TRF) Southern Blot  
 PBMC and anti-CD3/CD28 activated normal human PBMC (day 4 post-
stimulation) samples were magnetically purified using negative selection for CD3+ T 
cells according to supplied instructions (Pan T cell isolation kit II, Miltenyi Biotec). Cells 
were split into two aliquots each, one for TRF Southern blot DNA extraction and the 
other for telomere FlowFISH as described in section 2.E. above. 
 DNA was extracted from 2 x106 CD3+ T cells for TRF Southern blotting using the 
Wizard Genomic DNA purification kit (Promega).  DNA preparations were digested 
overnight with HinfI and RsaI restriction enzymes (New England BioLabs) in supplied 
buffers at 37oC. Electrophoresis of one microgram of digested DNA per lane was 
performed on a 0.8% tris-buffered saline (TBS)-agarose gel with TBS running buffer. 
Biotinylated-molecular weight (MW) markers were run in adjacent lanes. Samples were 
depurinated, denatured, neutralized and transferred overnight to a neutral membrane. The 
next day the membrane was dried, UV cross-linked, and hybridized with a telomere G-
strand-specific, fluorescein labeled PNA probe (FAM-OO-(CCCTAA)3). After 
stringency washes and blocking, the telomere bands were developed and visualized using 
a commercial chemiluminescence system (lluminator Chemiluminescent Detection 
System, Stratagene). The membrane was then stripped and biotinylated-MW bands were 
visualized using streptavidin-alkaline phosphatase chemiluminescence. Both images were 
overlayed and MW marks transferred to the telomere probe image and then scanned at 
1200 pixel per inch resolution. For determination of TRF lengths, the resulting scanned 
image was analyzed with the MatLab (MathWorks) macro MATELO (120). Using the 
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MATELO-MatLab computer-aided analysis, three 20 pixel-wide columns were 
simultaneously analyzed in each telomere band and the resulting TRF length outputs 
averaged to provide a TRF length result. 
 
I. Surface phenotype flow cytometry on BrdU labeled PBMC 
 Seven-color flow cytometry surface phenotype analyses were performed on all 
day 7 in vitro, BrdU-labeled PBMC samples. Samples consisting of 2x105 in vitro 
cultured cells were washed and stained for the following surface markers: CD3, CD4, 
CD8, CD45RA, CD27, and CD62L as described in Table 2.2. After staining, cells were 
washed to remove unbound antibodies, then 300 μL fixation-permeabilization solution 
(fix-perm, BD Biosciences) was applied for 20 minutes at 4oC and then washed in 1X 
perm-wash buffer (BD Biosciences). Samples were then incubated 10 minutes in perm-
wash buffer plus 10% DMSO at 4oC, washed, and incubated 5 minutes with 200 μL fix-
perm solution. After a perm-wash rinse of the cell pellets, samples were treated with 1 
mM DNase I (Sigma) plus 10 mM magnesium chloride in 200 μL perm-wash in sealed 
tubes for 1 hour at 37oC with occasional gentle vortexing. Samples were then washed one 
time in perm-wash buffer, and split to two separate staining tubes, one for PE-anti-BrdU 
and the other for PE-isotype control antibody staining. Samples were stained for 1 hour at 
room temperature with PE-anti-BrdU antibody or the matched IgG isotype control 
antibody (BD Biosciences).  Samples were washed and transferred to flow cytometry 
tubes for analysis on a FACS-Aria cytometer (BD BioSciences). 
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J. In vitro PBMC activation and telomerase activity measurement 
 Telomerase activity in stimulated PBMC was measured using a commercial PCR-
based, real-time telomerase repeat activity protocol kit (RT-TRAP, Millipore, Billerica, 
MA) per manufacturer’s instructions. Briefly, 106 PBMC from each sample were 
stimulated for three days with plate-bound anti-CD3 (clone OKT3, BD) and anti-CD28 
(clone 28.1, BD), each at 3 μg/mL in 2 mL complete RPMI-1640 media (Gibco-
Invitrogen) with 10% fetal calf serum. Cell lysates were prepared from harvested cell 
pellets and placed in -80oC frozen aliquots per manufacturer’s instructions using provided 
lysis buffer. RT-TRAP was performed per manufacturer’s instructions using 2000 cell 
equivalents per test well on a 96-well PCR plate. Real-time PCR was performed on an 
ABI Prism 7300 (Applied Biosciences). Using the unit equipped, real-time software 
(SDS v1.4), triplicate-averaged sample fluorescence threshold crossing values were 
converted, using kit-provided controls and template standards and the resulting standard 
curve template control values, to a mean telomerase product quantity for each sample. 
Telomerase activity (TA) results are a ratio of a triplicate-derived mean quantity to the 
same-plate, negative control mean quantity.  
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K. Statistical analysis 
 Statistical tests included linear regression testing, Student’s t-test, Mann-Whitney 
unpaired and Wilcoxon paired non-parametric tests, and Fisher’s exact test, and were 
performed using Prism version 5 (Graphpad) software. All tests were two-tailed. For 
Chapter 5, although subjects within the two randomization groups were initially selected 
as matched pairs, TL data from one subject was unusable and therefore unpaired analyses 
were conducted. For linear regression analyses, fitted lines, correlation values, and p 
values are from linear regression testing. Linear regression equation parameters of slope 
and intercept were determined by linear trend line fitting in MS Excel (Microsoft). 
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CHAPTER III 
 
MODIFIED FLOWFISH ASSAY DEVELOPMENT 
 
A. Early obstacles to using the flowFISH assay  
 The flowFISH assay was originally devised and described by Dr. Peter Lansdorp 
as a method to estimate TL in large numbers of intact cells using flow cytometry (109, 
110). This assay has been used and refined by Lansdorp and others to study TL in ex vivo 
peripheral blood cells, which are mostly quiescent, non-dividing cell populations (89, 
121-123). This chapter is devoted to describing the modification of flowFISH protocols 
to study TL in PBMC samples from the HALT-C trial (Chapter V) and in PBMC that 
were stimulated with viral antigens in vitro (Chapter IV). 
 For the studies of virus-specific memory T cells that will be described in Chapter 
IV, the major objective was to measure TL in virus-specific T cells that significantly 
proliferated in vitro. Our initial experiments with the established flowFISH assay met 
with some obstacles. Foremost among these was our consistent observation that TL 
estimates from flowFISH were inflated when we used activated, proliferating peripheral 
blood lymphocytes (cultured blasts). Simultaneous to developing the flowFISH TL assay 
for proliferated T cells, we also explored various antibody-fluorochrome staining 
combinations to discriminate CD4+ and CD8+ T cells within the lymphocyte population 
given the limitations imposed by the telomere probe hybridization conditions. Solutions 
to these two issues are described in sections B and C below.  
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 A major obstacle was the low frequency of antigen-specific T cells directed 
against the acute and latent virus infections we proposed to study. Use of HLA-peptide 
tetramer staining to identify antigen-specific T cells, as has been done by others (112), 
was not a desirable approach for several reasons. A tetramer would limit the analysis to 
CD8+ T cells specific for few MHC-restricted epitopes; an area where work on virus-
specific T cell TL had already been published by others. An additional consideration was 
the limited availability of cryopreserved PBMC samples with relevant HLA haplotypes 
for a longitudinal analysis. We therefore used an antigen stimulation protocol which 
predominantly stimulated CD4+ T cells for these studies. 
 Much early effort focused on using carboxy fluorescein succinimidyl ester 
(CFSE) dye dilution to identify in vitro proliferated cells directly within the flowFISH 
analysis. There were some early successes with this approach, but visualizing fluorescein 
in flowFISH-treated cells necessitated high concentration loading of CFSE onto the 
PBMC sample (data not shown). This high CFSE concentration inhibited antigen-driven 
proliferation in T cells. We next labeled cells with BrdU and found that the combination 
of flowFISH with BrdU labeling was suitable to identify T cells that proliferated in 
response to stimulation with viral antigen and measure their TLs. Section D of this 
chapter describes these results. 
 
B. Flow-FISH analysis of T cell telomere length in in vitro-expanded T cells  
 To determine how in vitro expansion may have affected TL, we initially 
compared TL in total T cells isolated from fresh PBMC to in vitro-expanded T cells, 
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using a published flow-FISH protocol (119). We found measures of TL based on probe 
fluorescence in expanded T cells that were much higher when compared to the same T 
cells directly ex vivo (p<0.001, Fig. 3.1.A left bars). However, TL of expanded T cells 
calculated from the flow-FISH assay were also higher than TL estimates from TRF 
Southern blotting (compare Fig. 3.1.B with Fig. 3.1.A left bars), which were similar for 
expanded T cells and those analyzed ex vivo. This suggested that the inflated flow-FISH 
TL estimate was an assay artifact rather than a result of in vitro expansion.  
 Telomeres had recently been shown to be transcribed, thereby creating RNA 
transcripts of the G-rich sequence telomere sequence (124, 125). In light of this finding, 
elimination of this potential RNA telomere probe target as a potential source of error in 
the DNA telomere length estimation in human T lymphocytes was deemed necessary. We 
therefore tested several modifications to the flow-FISH protocol. Inclusion of a pre-
hybridization fixation-permeabilization without RNA nuclease treatment reduced the 
probe fluorescence, resulting in mean TL estimates closer to the TRF results (Fig. 3.1.A 
middle bars). The combination of fixation-permeabilization with an optimized RNA 
nuclease treatment gave minimized background fluorescence for the telomere probe (Fig. 
3.1.C) and produced flow-FISH TL estimates in agreement with TRF results (Fig. 3.1.A 
right bars). Lead-in experiments to establish this optimal RNA nuclease concentration 
and treatment times are described below. 
 A series of preliminary experiments were designed and conducted to determine an 
RNA nuclease treatment time and concentration protocol for PBMC samples. Briefly, a 
highly abundant small nuclear RNA target, 7SK, was chosen to test RNA nuclease  
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Figure 3.1  Accurate telomere length (TL) measurement using flowFISH on 
proliferating T lymphocytes requires fixation-permeabilization and RNA nuclease 
treatment  
 
PBMC from healthy adults were divided to two aliquots, either stimulated with 
immobilized anti-CD3 and anti-CD28 for 4 days or cryogenically preserved on day 0 and 
thawed for processing on day 4; CD3+ T cells were magnetically sorted from both 
samples on day 4. Each resulting sample was divided for both flowFISH TL analysis and 
TRF Southern blotting. (A) FlowFISH analysis using 3 different pre-hybridization 
conditions: without fixation-permeabilization (no fix/perm), with fixation-
permeabilization (Fix/Perm), and with fixation-permeabilization followed by RNA 
nuclease treatment prior to hybridization (Fix/Perm +RNase). Statistical comparisons 
were done using unpaired t-test, *** p<0.001, and ns=not significantly different. These 
results are representative of four independent experiments. (B) Southern blot telomere 
restriction fragment (TRF) analysis of CD3+ T cell samples, directly ex vivo or anti-
CD3/CD28 stimulated for 4 days used in A. TRF lengths are shown at the bottom of both 
lanes and are the average of three separate 20 pixel-wide analyses using MatLab software 
running the MaTelo macro (see Methods). 
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treatments to verify nuclease access to nuclear-localized RNA and loss of probe signal 
with flow cytometry measurement. Lithium-based reagents were used to 
eliminate/prevent nuclease-resistant G-quadruplex structures, which telomeric sequences 
can readily form (126, 127).  
 RNA nuclease concentrations tested were 0, 10, 20, 40, and 80 U/mL at a fixed 
time of three hours. All RNA nuclease concentrations tested reduced the specific 7SK 
signal to the background fluorescence levels (Figure 3.2.A).  RNA nuclease treatment 
times were tested at 0, 1.5, 3, 5.5, and 7.5 hours incubation time at a fixed RNA nuclease 
concentration of 20 U/mL. Although all times above 1.5 hours reduced the 7SK specific 
signal to background levels, background (autofluorescence) in the no-probe samples rose 
at time points beyond 3 hours (Figure 3.2.B). These data demonstrated that incubation 
times between 1.5 to 3 hours were optimal. 
 Using these RNA nuclease treatment concentrations, we tested the telomere PNA 
hybridization signal to detect a DNA-only signal (Figure 3.2.C). These results indicated 
that a probe signal minimum for TL estimation occurred at an RNA nuclease 
concentration of 20 U/mL for 3 hours in agreement with the 7SK RNA nuclease results. 
Overall, these experiments demonstrated that a DNA-only telomere signal in T 
lymphocyte flowFISH could best be obtained with fixation-permeabilization followed by 
an optimized RNA nuclease treatment. 
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Figure 3.2  RNA nuclease treatment optimization for detecting a DNA-only telomere 
probe signal in human T cells  
  
(A) Effect of RNA nuclease concentrations (units/mL) on the sn7SK RNA target probe 
fluorescence (black line). Specific MFI is the Probe+ signal (blue line) minus the no-
probe (autofluorescence, green line) signal. (B) Effect of RNA nuclease incubation time 
on the sn7K RNA signal (blue line) and on autofluorescence (green line). (C) Effect of 
RNA nuclease treatment on the measurement of telomere length signal in T cells 
analyzed directly ex vivo by flowFISH. Specific MFI is the difference between the 
average signal in triplicate probe+ tubes and the background fluorescence in the probe-
minus tube. These results are from the CD45RA+ gate, similar results for RNA nuclease 
treatment were obtained in the CD45RA- population. T cells were purified from PBMC 
using magnetic separation. p values were determined by Student’s t-test on triplicate 
hybridizations. Limit of detection for mean fluorescence intensity (MFI) was 0.4 arbitrary 
units (AU). Error bars are standard deviation. 
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C. FlowFISH discrimination of CD4+ and CD8+ T cells 
 Various anti-CD4 and anti-CD8 antibodies conjugated to heat-stable 
fluorochromes were tested for adequate discrimination of these two T cell populations 
(data not shown). Based on these results, we settled upon the staining combinations listed 
in Table 2.2. The hybridization conditions reduced the intensity of CD8+ staining 
compared to the same staining without hybridization (Figure 3.3). Nevertheless, 
CD4+CD8- and CD4-CD8+ T cell subsets could still be clearly discriminated. 
 CD45RA and CD57 are two of the cell surface phenotypic markers that have been 
shown to survive flowFISH hybridization and can be stained post-hybridization (123). 
CD45RA is the high molecular weight isoform of the very abundant surface molecule 
CD45 and is expressed by naïve T cells and by limited numbers of memory T cells. 
CD57’s role in lymphocyte biology is currently unclear. However, CD57 expression on 
lymphocytes has been established as a surrogate marker to identify terminally 
differentiated, high cytotoxic capacity T cells with limited or no replicative potential 
(128-130). 
To enable further subset discrimination, we used post-hybridization staining with 
antibodies directed against CD45RA and CD57. Within each of these subsets, CD45RA 
discriminated memory (CD45RA-) T cells from the mostly naïve (CD45RA+) T cell 
subset and CD57 further enhanced discrimination of naïve (CD45RA+ CD57-) T cells 
from CD57+ T cell effector-memory re-expressing CD45RA+ (TEMRA) (129). 
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Figure 3.3  Flow cytometry gating for direct ex vivo analysis of telomere length in 
CD4+ and CD8+ PBMC subsets  
 
Forward-scatter area by forward-scatter height gating was used to reduce cell aggregates 
(doublets). Singlet cells in the G0/G1 (to ensure diploid DNA content) gate were further 
selected using a lymphocyte gate based on forward and side scatter profiles. Flow plots of 
CD4+ by CD8+ staining with and without hybridization are shown. Conversion of mean 
fluorescence intensities (MFI) to Molecules of Equivalent Soluble Fluorescence (MESF) 
produced TL estimates for all subsets. A minimum 30 events-per-gate cut-off was used to 
ensure sufficient numbers of single cell measurements for TL estimation – limit that only 
limited CD57+ populations estimates. This lower limit on the number of events in a gate 
serves to ensure the MFI value derived from that gate is of sufficient size to ensure a 
random sample. 
 
 
 
 
 
48 
D. TL measurement in T lymphocytes that proliferated in vitro to viral antigens 
 To identify T cells that proliferated to virus antigen, we labeled cells with BrdU 
during the final 72 hours of incubation and stained with anti-BrdU after telomere probe 
hybridization. We were able to clearly detect a well separated and distinct population of 
BrdU+ cells (Figure. 3.4.A). Thus the flowFISH protocol readily accommodated anti-
BrdU staining as a post-hybridization step. The use of the CD45RA marker allows for TL 
measurement in the mostly naïve, non-proliferated (CD45RA+ BrdUneg) T cell subsets. 
The mTL of this naïve population provides a point of reference for each individual to 
assess relative TL differences in the virus-specific BrdU+ populations. Relative changes 
of naïve T cell TL relative to virus-specific T cell TL changes in an individual could be 
important in the interpretation and modeling the kinetics of TL gain or loss. Virus-
specific CD4+ and CD8+ BrdU+ cells from a typical subject are shown in Figure 3.4.B. 
To elucidate the diversity in telomere lengths in each BrdU+ sample beyond a 
mean TL, flow-FISH also provides median TL and the coefficient of variation (CV) 
(Figure 3.4.C). Mean TL fluorescence values greater than median values are an indication 
of rightward skewed TL distributions, e.g. an elevated frequency of long telomere cells.  
The long telomere state of a cell becomes a significant consideration when the replicative 
capacity encoded within an extra kilo-base (kb) of TL would, as rough rule-of-thumb, 
allow for 10 population doublings of a progenitor cell. Ten population doublings 
represents a potential 1000-fold expansion capacity. This insight to distribution of 
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  BrdU-flowFISH allows for TL measurement in proliferating T cells  
 
(A) Flow cytometry gating strategy selects single cells (singlets), G0G1 diploid cells, and 
lymphocytes. CD4+ and CD8+ T cells are then gated for FSC-Ahigh BrdU+ as the 
proliferated virus-specific T cell for TL estimation. (B) Representative proliferative 
responses (BrdU+ FSC-Ahigh population) of CD4+ and CD8+ T cells to viral antigen. 
Values shown are frequencies of CD4+ or CD8+ T cells that are BrdU+. (C) Histograms 
of TL distribution for the virus-specific CD4+ T cell responses shown in B.  Mean and 
median fluorescence intensity values, in arbitrary units (AU), and coefficient of variation 
(CV) values for each population quantifies virus-specific TL distribution variation.  
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 TLs across heterogeneous cell populations is lost in TL assays such as TRF Southern 
blotting or quantitative PCR methods (109). 
 The naïve T cell TL measurement in cells cultured in vitro correlated well with 
TL measurements in CD45RA+ cells ex vivo (Figure 3.5.A). Replicate experiments using 
the same donor PBMC samples were performed to understand the variability of the 
flowFISH assay. Experiments on the same PBMC samples showed that TL measurements 
in proliferating (virus-specific) T cells were reproducible within and between assays 
(Figures. 3.5.B and C).  
  
E. Chapter Summary 
 
 Modification of the flowFISH assay to measure TL in proliferating cells led to the 
adoption of a fixation-permeabilization with RNA nuclease treatment of the cells. Recent 
discoveries of telomere biology by others in normal human T lymphocytes may explain 
the mechanisms behind why this treatment protocol brought the resulting TL estimates 
into agreement with a TRF Southern blot TL estimate (124, 125, 131). This topic is 
explored more fully in Chapter VI, Discussion. Further modifications allowed for CD4+ 
and CD8+ discrimination within the lymphocyte gating strategy. This flowFISH assay 
subsequently was used to measure T cell TL on direct ex vivo PBMC samples from a 
clinical trial of interferon therapy (Chapter V). Extension of this assay to incorporate 
BrdU staining for identification of proliferated cells allowed TL measurements in virus-
specific T cells (Chapter IV). The elucidation of TL distributions by flowFISH may be 
important to understanding the maintenance of replicative capacity in T cell memory. 
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Figure 3.5  Reproducibility of telomere length measurements by flowFISH assay  
 
(A) Comparison of TL measured directly ex vivo by flowFISH versus in BrdUneg T cells 
at day 7 of culture in three different subjects. (B) FlowFISH TL measurements in virus-
specific CD4+ T cells and in CD45RA+ (RA+) or CD45RA− (RA−) T cells from the same 
subject in two different experiments performed several months apart. (C) Intra-assay 
variability in TL measurement was assessed with replicate influenza virus-stimulated cell 
cultures tested in the same experiment (dotted and solid lines). Inset panel is the mean 
telomere probe fluorescence and BrdU+ cell frequencies. Histograms represent 
distribution of telomere length from diploid-gated BrdU+ CD4+ T lymphocytes. AU is 
arbitrary units of fluorescence.  
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CHAPTER IV 
 
 
 
 TELOMERE LENGTH DYNAMICS IN HUMAN MEMORY T CELLS  
 
SPECIFIC FOR VIRUSES  
 
CAUSING ACUTE OR LATENT INFECTIONS 
 
 
T cell proliferative responses to acute or latent virus infections have been detected 
decades after the initial infection (44, 47, 70, 94, 132) but how this T cell memory is 
established and maintained is not clear. The relationships between T cell proliferation, 
differentiation status, telomere length (TL) and subsequent ability to maintain effector 
functions in vivo are areas of intense study. TL has been shown to be a critical 
determinant of T cell replicative capacity and in vivo persistence in humans; adoptive 
transfer of tumor-infiltrating lymphocytes with long telomeres correlated with better in 
vivo persistence and proliferation, while excessive in vitro expansion leading to 
shortened telomeres correlated with poor in vivo persistence (96, 97).  
 Here we tested the hypothesis that TLs in T cells specific for acute, non-recurring 
viruses would be longer than TLs in T cells specific for recurring virus infections. We 
based this hypothesis on the observations that recurring or re-activating viral infections 
(or recurring presentation of viral antigens, e.g., from vaccination) drive additional 
rounds of in vivo clonal expansions thus lowering TL. Using PBMC from healthy adult 
donors, we examined TLs in T cells that proliferated in vitro to four viruses; two latent-
reactivating herpesviruses, CMV and VZV, and two viruses associated with acute 
infection, influenza A virus (IAV), and VACV. We used bromodeoxyuridine (BrdU) 
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labeling as described in Chapter III to detect memory T cells that proliferated in vitro in 
response to these viruses, and then used flowFISH to measure TL in virus-specific 
(BrdU+) cells. We performed a cross-sectional study of virus-specific memory T cell TL 
in ten healthy adults, with a longitudinal study involving five of these subjects. 
 
A.  TL measurement in T lymphocytes that proliferate to viral antigens 
 Since TL declines in normal somatic cells as a result of cell division, and because 
our hypothesis was based on TLs in vivo, it was important to understand the effects of in 
vitro expansion on the measured TL in virus-specific T cells. Prior to day 5, CD4+ BrdU+ 
cells were not detectable above the background frequency in negative control 
(unstimulated) cultures (data not shown). Starting at day 5, BrdU+ cells represented a 
small percentage of total CD4+ T cells but were present as a distinct population compared 
to unstimulated cultures (Figure 4.1.A); the BrdU+ cell population increased in frequency 
over the next several days. However, day 5 and 6 cultures had T cell populations with 
low BrdU+ cell numbers and skewed TL distributions, which combined to produce high 
variability in measured mean TL at these time points (Figure 4.1.B, and data not shown). 
In contrast, at day 7 of culture, TL distributions had converged to more Gaussian-like 
distributions (Figure 4.1.B) where the impact on mean TL of elevated numbers of outlier 
long telomere cells in a small total number of cell was reduced. 
 Previous work by others showed that the phenotype of Epstein-Barr virus-, 
VACV-, and yellow fever virus-specific CD8+ T cells converts in vivo over several 
months after viral infection from an early population of proliferating, CD45RA-
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/CD45RO+ effector T cells to mostly quiescent, CD45RA+ memory T cells with a high 
replicative capacity (111, 133). Consistent with these results we found higher CD45RA+  
frequencies in the proliferated fraction during day 5 and day 6, where the CD45RA- 
fraction increased over the same period to become the dominant phenotype within the 
BrdU+ population at day 7 (Figure 4.1.C). 
 The results for the virus-specific CD8+ T cells were similar to the findings in 
virus-specific CD4+ T cells (Figure 4.2.A and B). However, interpretation of the TL in 
CD8+ T cells warrants caution. The normal CD4+: CD8+ ratios in PBMC result in lower 
total numbers of cells to analyze in flowFISH, and the use of viral antigen preparations 
rather than peptide mixtures may have produced sub-optimal virus-specific CD8+ 
stimulation. For these reasons we excluded CD8+ results from further cross-sectional and 
longitudinal modeling. 
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Figure 4.1  TL and CD45RA+ frequencies in proliferating CD4+ T cells  
 
(A) BrdU+ CD4+ T cells were enumerated on the indicated days after in vitro stimulation 
with viral antigens. BrdU was added to wells 3 days before harvest in all cases. (B) 
Histograms of TL in BrdU+ cell populations from A. Values indicate the frequencies of 
long telomere cells. (C) Distribution of TL and CD45RA staining in BrdU+ cells from A. 
Values indicate the percentages of CD45RA- and CD45RA+ cells in each sample. Data 
are representative of two independent experiments. 
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Figure 4.2  TL and CD45RA+ frequencies in proliferating CD8+ T cells   
 
(A) BrdU+ CD8+ T cells were enumerated on the indicated days after in vitro stimulation 
with viral antigens. BrdU was added to wells 3 days before harvest in all cases.  
(B) Histograms of TL in BrdU+ cell populations from A. Values indicate the frequencies 
of long telomere cells. (C) Distribution of TL and CD45RA staining in BrdU+ cells from 
A. Values indicate the percentages of CD45RA- and CD45RA+ cells in each sample. Data 
are representative of two independent experiments.  
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B. CMV-specific and VACV-specific CD4+ T cells have longer mean telomere 
lengths than IAV-specific CD4+ T cells  
 Nine of ten subjects had CD4+ T cells that proliferated to CMV, and all ten 
subjects had CD4+ T cells that proliferated to IAV, VACV and VZV (Table 4.1). Our 
analysis of PBMC from these ten healthy adult subjects indicated that stimulation with 
IAV produced the highest frequency of proliferating CD4+ memory T cells (percent 
BrdU+) (Figure 4.3.A, p<0.05 by Wilcoxon paired analysis). Frequencies of CD4+ T cells 
that proliferated to CMV were generally lower than for the other three viruses, but were 
very high in two subjects. 
 Analysis of naïve (non-proliferated, CD45RA+ from media-only cultures) and 
virus-specific CD4+ T cells in our cohort of ten healthy subjects, who ranged in age from 
26 to 61 years, produced a wide range of mean TL (Figure 4.3.B). In pair-wise 
comparisons, VACV-specific CD4+ T cell TL were significantly longer than IAV-
specific CD4+ T cells, in both absolute TL (p<0.01, Figure 4.3.C) and as a ratio to the 
subject’s naïve T cell TL (Figure 4.3.D). Counter to our hypothesis, we found that CMV-
specific CD4+ T cell TL was also significantly longer than IAV-specific CD4+ T cell TL 
(p<0.05) in both absolute TL and as a ratio to naïve T cell TL. Important to the 
interpretation of these results, TL in proliferating T cells showed no correlation with the 
percent BrdU+ cells (Figure 4.3.E), indicating that the differences in TL were not an 
artifact of the amount in vitro expansion.  
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Figure 4.3  TL in CMV- and VACV-specific CD4+ T cells are longer than TL in 
IAV-specific CD4+ T cells  
 
(A) Frequencies of BrdU+ CD4+ T cells in ten healthy adults. (B) Mean TL measured in 
CD4+ T cells grouped by subject in units of molecules of equivalent soluble fluorescence 
(MESF). (C) Absolute TL in CD4+ T cells grouped by virus. (D) TL in CD4+ T cells that 
proliferated to viral antigen normalized to TL in naïve CD4+ T cells (BrdUneg CD45RA+) 
(TL/TLnaïve) in the same subject. Statistical analyses: ** p < 0.01, * p < 0.05 by Wilcoxon 
paired, signed rank test. (E) Linear regression analyses for correlations between virus-
specific proliferation frequencies (% BrdU+) and TL/TLnaive. P values are from linear 
regression testing. For CMV, n=9; all others, n=10. 
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C. CMV-specific and VACV-specific CD4+ T cells have a more effector-like 
phenotype  
 Standard flow cytometry surface phenotype analyses were performed in parallel 
with the flow-FISH TL analysis on these BrdU-labeled in vitro cultures (Figure 4.4.A). 
VACV-specific CD4+ T cells had a higher frequency of CD62Llow cells than IAV-
specific and VZV-specific CD4+ T cells (Figure 4.4.B). Additionally, CMV-specific 
CD4+ T cells had a higher frequency of CD62Llow phenotype cells compared to IAV-
specific CD4+ T cells. These data suggest that VACV-specific and CMV-specific CD4+ T 
cells have a more effector-like phenotypes than IAV-specific CD4+ T cells. 
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Figure 4.4  In vitro expanded CMV- and VACV-specific CD4+ T cells display a 
more effector-like phenotype than IAV-specific CD4+ T cells  
 
Surface phenotyping was performed on all day 7 cultures using standard flow cytometry 
staining. (A) Flow cytometry gating of virus-specific memory (BrdU+) T cells employed 
the analysis of CD62L and CD27 surface expression as shown. (B) Frequency of 
CD62Llow (effector memory phenotype) T cells within BrdU+ CD4+ CD3+ T cells.  
CD62Llow frequency (in percent) is the sum of the lower two quadrants of the CD27 by 
CD62L flow plots shown in A. * p < 0.05 by Wilcoxon paired, signed rank test.  
Horizontal bars are median values. CMV, n = 9, all other virus-specific results, n = 10. 
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Figure 4.5  Surface phenotypes of virus-specific memory BrdU+ CD4+ CD45RA+ T 
cells  
 
(A) CD62L expression was not different between CD45RA+ and CD45RA- virus-specific 
CD4+ T cells. P > 0.1 for all pair-wise (CD45RA+ versus CD45RA-) comparisons in A. 
(B) CD27 expression was higher in CD45RA+ than CD45RA- virus-specific CD4+ T 
cells. Note: CD27 data was only available for 8 of 10 donors. Statistical tests by 
Wilcoxon paired analyses, * p < 0.05, ** p < 0.01. Plots are box-whisker min to max 
plots. 
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D. VACV-specific memory CD4+ T cells include a higher frequency of CD45RA+ 
cells with long telomeres. 
 In the course of these studies, we observed the consistent presence of BrdU+ cells 
with long telomeres in day 7 virus-stimulated cultures (Figure. 4.1.B), nearly all of which 
were CD45RA+. Surface phenotype analysis showed that the proliferated (BrdU+) 
CD45RA+ T cells had CD62L expression equivalent to the larger CD45RA- fraction of 
virus-specific T cells (Figure 4.5.A). Compared to the virus-specific CD45RA- T cells, 
CD27+ expression was higher in the CD45RA+ virus-specific T cells, suggestive of a 
cellular phenotype receptive to co-stimulation (Figure 4.5.B). The CD45RA+ fraction 
typically constituted 5-15% of BrdU+ cells in all four virus-stimulated cultures at day 7 
(Figure 4.6.A), and was skewed toward longer TL compared to the CD45RA- population 
(Figure 4.6.B  histograms). Skewing of the TL distributions in the CD45RA+ sub-
population is further indicated by mean fluorescence intensities higher than the median 
values (Figure 4.6.B), in contrast to the CD45RA- population. 
We compared the frequency of long telomere CD4+ CD45RA+ cells in our cohort. 
For this analysis, we applied an arbitrary, but consistent telomere probe cutoff value for 
each subject (Figure 4.6.C). We found that the frequencies of long telomere CD45RA+ 
cells were significantly greater in VACV-specific T cells than in IAV-specific T cells 
(p=0.03, Figure 4.6.D).  
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Figure 4.6 VACV-specific memory CD4+ T cells have a higher frequency of 
CD45RA+ cells with long telomeres  
 
(A) CD4+ T cell proliferative responses (BrdU+) gated by CD45RA+/-from 1 subject. 
Histograms of TL in CD45RA- and CD45RA+ cells are overlaid, and mean and median 
fluorescence intensities for each population are shown. (B) Mean and median telomere 
probe fluorescence intensity values for all subjects’ grouped by virus. Box and whisker 
plots indicate minimum to maximum values with the lines inside the boxes depicting the 
median values for each set of measurements. (C) Frequencies of BrdU+ CD45RA+ CD4+ 
T cells with long telomeres in a representative subject.  (D) Frequency of CD45RA+ 
CD4+ T cells with long telomere within the BrdU+ population for 10 subjects. * p < 0.05 
by Wilcoxon paired, signed rank test. Fluorescence is shown in arbitrary units (AU). 
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E. Longitudinal analysis of virus-specific CD4+ T cell telomere dynamics in healthy 
subjects. 
 For five of our subjects, we had multiple PBMC samples collected over an 8 to 10 
year interval.  We compared TL of naïve (CD45RA+ BrdUneg) and virus-specific CD4+ T 
cells from the first and last time points grouped by subject (Figure 4.7.A) and by virus 
(Figure 4.7.B). We also used the average slopes and y-intercepts to graph the average TL 
kinetics (dashed lines in Figure 4.7.B). Naïve (CD45RA+ BrdUneg) CD4+ T cells in all 
subjects showed a downward slope, consistent with age-dependent TL erosion (88). 
Virus-specific CD4+ T cells also showed declining mean TL in the cohort as a whole; 
however, TL in CMV-, IAV-, or VZV-specific CD4+ T cells increased from the first to 
last time point in at least 1 subject.  
 The mean TL slopes (rate of TL decay) in both CMV- and IAV-specific CD4+ T 
cells were similar, while both the VACV- and VZV-specific slopes were steeper and 
similar to the naïve TL decay rate (Figure 4.7.C). The differences in TL slopes did not 
reach statistical significance in this small cohort, however (n=5, p=0.06).  
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Figure 4.7  Longitudinal analysis of TL in virus-specific CD4+ memory T cells.  
 
(A) TL was measured in naïve CD4+ (BrdUneg CD45RA+) (dotted lines) and BrdU+ CD4+ 
T cells (solid lines) from five healthy subjects. PBMC samples were obtained 8 to 10 
years apart. (B) The data from A were grouped according to different virus-specific T cell 
populations for all 5 subjects. Dotted lines derive from the average slopes and y-
intercepts. (C) Average TL kinetics of each virus-specific T cell population and naïve T 
cells are redrawn from B. 
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F.  VZV reactivation was associated with an increase in VZV-specific T cell 
 
telomere lengths and proliferative responses  
 
 From one healthy subject, we had obtained three PBMC samples over a period of 
three and a half years. We observed an increase in both the frequency and mean TL in the 
VZV-specific CD4+ (Figure 4.8.A, C) and CD8+ (Figure 4.8.B, D) T cells at the middle 
time point in this subject. This individual reported an episode of shingles approximately 
2-3 weeks prior to the blood draw for the middle time point. These results suggest that a 
herpesvirus reactivation can lead not only to a boost in the memory T cell frequency but 
also to increased TL in T cells. 
We further analyzed the CD45RA+/- expression in VZV-specific CD4+ and CD8+ 
T cells in this subject (Figure 4.8.E). While TL in CD4+ CD45RA+ BrdU+ T cells was 
not different from TL in CD4+ CD45RA- BrdU+ T cells before VZV reactivation, it was 
significantly higher after VZV reactivation (Figure 4.8.F), indicating that prior to 
reactivation the long telomere characteristic of the VZV-specific CD45RA+ CD4+ T cell 
was lost. Overall, these results suggest a picture of waning CD4+ assisted T cell control to 
VZV reactivation is not simply a decline in virus-specific T cell frequency. Reduced 
proliferative capacity as TLs diminish would eventually lead to loss of the high 
replicative capacity CD45RA+ component. Robust VZV reactivation in the form of 
shingles with active viral replication may then lead to recruitment of naïve T cells to re-
establish T cell control of viral replication with a corresponding increase in proliferative 
frequency and TL, as seen in this subject. 
 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8  VZV reactivation was associated with an increase in proliferative 
responses and TL in VZV-specific CD4+ and CD8+ T cells  
 
Dot plots show virus-specific (A) CD4+ and (B) CD8+ proliferative responses across 
three time points in the same subject. BrdU+ frequencies (percent) are shown in the gate. 
PBMC were collected approximately two years prior (top row), two weeks after (middle 
row) or fourteen months after (bottom row) VZV reactivation. Graphs depict mean TL in 
(C) CD4+ and  (D) CD8+ T cells along with TL in naïve T cells (media-only culture 
BrdUnegCD45RA+) (dashed line) across the three time points. (E) VZV-specific CD4+ 
and CD8+ T cell from A and B are further delineated by CD45RA expression. (F) Mean 
TL for VZV-specific T cells by CD45RA expression. Error bars are standard errors from 
triplicate hybridizations of the same sample. By unpaired t-test, *** p < 0.001, ** p < 
0.01, ns = not significantly different. 
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G. Chapter Summary 
Declining telomere length (TL) is associated with age-related T cell senescence, 
but there are few data on TL in virus-specific T cells. Using BrdU-flowFISH and PBMC 
from ten healthy adults, we tested the hypothesis that recurring-acute (IAV) or 
reactivating (VZV and CMV) viruses would generate memory T cells with shorter TL 
than a non-recurring acute viral infection (VACV); five subjects provided multiple 
PBMC samples separated by up to 10 years. Our results indicate that VACV-specific and 
CMV-specific CD4+ memory T cells had longer telomeres than IAV-specific CD4+ T 
cells. Although most virus-specific (BrdU+) cells were CD45RA-, we observed a minor 
population (5-15%) of BrdU+ CD45RA+ T cells characterized by long telomeres. 
Analysis of sequential PBMC samples demonstrated a slow decline in TL in virus-
specific T cells, even in the absence of re-exposure. However, in one subject, VZV 
reactivation led to a significant increase in TL in virus-specific T cells, suggesting 
recruitment of longer telomere naïve cells to memory.  
Declining TL with age was reproduced in the cross-sectional/longitudinal model. 
TL in virus-specific memory T cells generally declined as in the naïve T cell 
compartment, but the kinetics of these declines appeared to differ – a topic more fully 
explored in Chapter VI. The observation that herpesvirus reactivation can substantially 
refresh specific T cell memory TLs has important implications that are also explored in 
Chapter VI. We conclude that TL in memory T cells that are able to proliferate to viral 
antigens is dynamic, and that TL distribution is important to understanding the 
maintenance of long-lived T cell memory. 
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CHAPTER V 
 
EXTENDED INTERFERON-ALPHA THERAPY ACCELERATES TELOMERE 
LENGTH LOSS IN HUMAN PERIPHERAL BLOOD T LYMPHOCYTES 
 
Type I interferons have pleiotropic effects on host cells, including inhibiting 
telomerase in lymphocytes and antiviral activity. Combination pegylated-IFNα (peg-
IFNα) with ribavirin is the standard therapy for subjects with chronic hepatitis C virus 
(cHCV) infection. There are additional clinical settings where extended interferon 
therapy is utilized, such as relapsing-remitting multiple sclerosis and melanoma (134, 
135). How IFN modulates TL in peripheral naïve and memory T cells is currently 
unclear. 
The aim of this study was to examine the effects of long-term peg-IFNα therapy 
on TL in peripheral blood T lymphocytes. The PBMC used in this study were obtained 
from patients enrolled in the Hepatitis-C Antiviral Long-term Treatment against Cirrhosis 
(HALT-C) trial (113). We used a flowFISH assay described in Chapter III, Section D to 
measure TLs in naïve and memory T cells at baseline (S00) and at months 21 (M21) and 
45 (M45) of the trial in 29 HCV-infected subjects. The subjects included in our study had 
failed to achieve a sustained virologic response following 24 weeks of pegylated- IFNα 
plus ribavirin treatment and were subsequently randomized to either a no additional 
therapy group (no therapy group) or a maintenance dose of pegylated-IFNα group (peg-
IFNα group) for an additional 3.5 years as described in Chapter II, Figure 2.1. 
Additionally, we used a commercial telomerase repeat activity protocol (TRAP) assay on 
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in vitro stimulated PBMC samples, as detailed in Chapter II, Materials and Methods, to 
assess telomerase activity between the therapy group and control group samples.  
 
A. Baseline characteristics of patients 
The clinical characteristics of the subjects involved in this study are shown in 
Chapter II, Table 2.1. There were no significant differences in these clinical 
characteristics at baseline between the peg-IFNα and the no-therapy group. We measured 
baseline TL in T cell subsets from this cohort.  TLs in naïve (CD45RA+ CD57-) T cells 
were greater than TLs in memory (CD45RA- CD57-) T cells, consistent with prior reports 
(88, 119).  Average TLs in CD57+ T cell subsets were shorter than their corresponding 
CD57- subsets (Figure 5.1.A). The percentage of CD57+ cells was higher in the CD8+ T 
cell compartment than in the CD4+ T cell compartment (Figure 5.2.B), consistent with 
published results (129). No correlation existed between subject age and TL in the cHCV 
cohort (Figure 5.1.B left panel). In contrast, we found an expected inverse correlation of 
age and TL in a separate cohort of 19 healthy subjects (Fig 5.1.B right panel) (88, 136). 
There were no significant differences in TL for any of the T cell subpopulations between 
the peg-IFNα group and the no-therapy group at baseline (Figure 5.2.A).  
We next compared viremia levels and body mass index (BMI) with TLs in T cells at 
baseline. HCV viremia levels inversely correlated with TL in total CD4+ and CD8+ T 
cells (Figure 5.3.A), naïve T cells (Figure 5.3.B), and memory T cells (Figure 5.3.C) at 
baseline. BMI at baseline also inversely correlated with TL in naïve CD4+ and CD8+ T 
cells (Figure 5.3.D). However, there was no significant correlation between HCV viremia 
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Figure 5.2  Baseline telomere lengths were not different between the IFN treatment 
and control groups 
 
(A) Subject telomere lengths at baseline.  Each symbol is an individual subject’s TL 
measured by flowFISH in that T cell subset. P values are from unpaired t test analysis. 
Horizontal bars are mean values. (B) CD57+ subset distribution within respective CD4+ 
and CD8+ T cell populations from baseline (S00), month 21 (M21), and month 45 (M45). 
Plots are box and whiskers 5-95 percentile bar graphs showing outlier values; peg-IFNα 
therapy subjects shown as empty bars; control group subjects, filled bars.  RA+ or RA- 
indicates CD45RA+ or CD45RA- respectively, 57+ indicates CD57+. 
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levels and BMI (data not shown), suggesting that BMI and viremia are independent 
factors associating with T cell TL in chronic HCV infection. 
 
B. Sustained IFNα therapy was associated with increased loss of telomere length 
To determine whether IFN therapy affected telomere erosion, the rate of change 
in TL in CD4+ and CD8+ T lymphocyte subsets between baseline (S00), month 21 (M21) 
and month 45 (M45) was determined for both groups (Figure 5.4). The average slopes 
derived from the linear regression equations for each subject (delta TL/year in units of 
MESF) showed declining TL for all T cell subsets. The average linear regression slopes 
between S00 and M45 show higher average rates of TL loss in the peg-IFNα treatment 
group for total CD4+ T cells (Figure 5.4.A), total CD8+ T cells (Figure 5.4.D), naïve 
CD4+ and CD8+ T cell subsets (Figs. 5.4.B, E) and memory CD4+ and CD8+ T cell 
subsets (Figs. 5.4.C, F), although this difference was statistically significant only for 
naïve CD8+ T cells (p=0.005). CD57+ T cells within both CD4+ CD45RA+/- and CD8+ 
CD45RA+/- subsets showed no difference in TL between treatment groups (data not 
shown).  
 The mid-point (M21) samples allowed assessment of whether the peg-IFNα effect 
on TL was linear over the four year study period. Within the peg-IFNα group, TL loss 
was greater in the first interval, S00 to M21, in the naïve CD8+ (p=0.002), memory CD8+ 
(p=0.03) and naive CD4+ subsets (p=0.02) compared to the M21 to M45 interval (Figure 
5.5). Naïve CD8+ T cell TL loss was higher in the treatment compared to control group in 
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Figure 5.4  Accelerated telomere length (TL) loss in naïve T cell subsets for the IFN 
group (figure previous page)  
  
Individual TL trajectories for (A) all CD4+, (B) naïve CD4+ (CD45RA+ CD57-), (C) 
memory CD4+ (CD45RA- CD57-), (D) all CD8+, (E) naïve CD8+ (CD45RA+ CD57-), and 
(F) memory CD8+ (CD45RA- CD57-) T cell subsets are shown for peg-IFNα subjects 
(left panels) and the no-therapy, control subjects (right panels). Solid lines connect the 
TL of each subject at three time points plotted by age at blood draw. The dashed line on 
each plot derives from a linear regression based on the averaged slope and y-intercept 
from each individual’s linear regression equation, with the average slope (± standard. 
deviation) in MESF per year of age shown in the upper right corner. 
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the first interval (p = 0.006), but not different in the second interval. Taken together, 
these analyses indicate that TL loss accelerated with peg-IFNα treatment, but only in the 
first study interval. 
 
C. Age dependence of accelerated telomere length loss 
 To assess the effects of age, treatment group, and TL changes, mixed-effects 
statistical analyses were performed with results indicating a significant age-related IFN-
effect on TLs (data not shown). However, linear model fitting assumptions inherent to a 
multivariate, mixed effects model were not consistent with the non-linear TL loss data 
across the three time points. We therefore partitioned the data set into three age 
categories: <50 years, 50 to 55 years, and >55 years of age at baseline (Figure 5.6.). The 
50-55 year partition was centered on the average age of our subjects (Chapter II, Table 
2.1), with the age partition boundaries selected to roughly balance the numbers of 
subjects in each partition. This age-partitioned analysis corroborated the mixed-effects 
model results in that accelerated TL loss in the peg-IFNα group was seen in subjects <50 
years old and that the effect was lost with increasing age in both CD4+ and CD8+ naïve 
and memory compartments.  
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D. Telomerase activity in T cells activated in vitro  
 
 We asked whether effects of long-term IFN therapy on telomerase activity (TA) 
could explain the accelerated TL loss. As resting peripheral blood T cells express little or 
no TA (88), we analyzed TA after in vitro activation as an indication of a possible 
durable effect of peg-IFNα therapy. No difference was detected in TA after in vitro 
activation between the two treatment groups (Figure 5.7). 
 
E.  Serum ALT-AST values inversely correlated with TL changes in the control 
group 
 Serum alanine aminotransferase (ALT) and serum aspartate aminotransferase 
(AST) levels are commonly measured in the clinical setting to monitor liver pathology. 
Since liver injury in cHCV is hypothesized to be related to T cell activation (50, 52), we 
examined the relationship between serum ALT and AST and T cell TL. We found that 
TL change (S00 to M45) in naïve CD4+ T cells and CD8+ T cells negatively correlated 
with the average serum ALT levels (p=0.016 and p=0.006, respectively) during the 
randomization phase in the control but not the peg-IFNα group (Figure 5.8). Average 
AST levels during randomization also inversely correlated with TL loss in naïve CD4+ T 
cells and CD8+ T cells (p=0.03 and p=0.006, respectively) during the randomization 
phase in the control but not the peg-IFNα group  (data not shown). These ALT-AST 
associations with telomere loss were not seen in the memory (CD45RA- CD57-) subsets 
(p >0.1, data not shown). These data suggest that TL loss is related to on-going liver 
disease activity, but only in the absence of exogenous IFN therapy.
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Figure 5.7  Induced telomerase activity in PBMC between treatment groups was not 
different at any time point  
 
Telomerase activity (TA) was assessed in in vitro stimulated PBMC from each of the 
three time points, baseline (S00), month 21 (M21), and month 45 (M45), and the results 
analyzed between treatment groups as shown. Statistical p values are from Mann-
Whitney non-parametric analysis. PBMC were stimulated with plate-bound anti-CD3 
plus anti-CD28 for 3 days and then tested for TA by a commercial real-time PCR-based 
TRAP assay as described in supplemental methods. 
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F. Sustained IFNα therapy suppressed TEMRA expansion 
Analysis of the CD57+ T cell subsets indicated these CD4+ and CD8+ T cell sub-
populations did not incur accelerated TL loss in the IFNα therapy group (data not shown). 
This result is consistent with previously published reports that CD57+ is a marker for T 
cells with limited replicative capacity, and thus a limited ability to further erode telomere 
length (31, 128). Oligoclonal CD8+ CD57+ T cell expansions have been reported as a 
marker for reduced responses to IFNα therapy in cHCV patients (137). Thus we 
undertook further analyses of the changes in the frequency of the CD57+ subsets within 
our cHCV cohort. The CD8+ CD45RA+ CD57+ subset, which is primarily a TEMRA 
population of highly differentiated T cells (31), declined in frequency (p=0.042) in the 
peg-IFNα group between S00 and M21, followed by no significant change from M21 to 
M45 (Figure 5.9, left panel). In contrast, the control group showed no significant change 
in the CD8+ CD45RA+ CD57+ T cell frequency between S00 and M21, followed by an 
increase between M21 and M45 (p=0.0001; Figure 5.9, right panel). These data suggest 
sustained therapy suppressed the accumulation of highly differentiated CD8+ T cell 
memory oligoclonal expansions, results consistent with the ability of type I interferon to 
induce lymphopenia (87, 138, 139). 
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G. Chapter Summary 
 Our data demonstrate significant telomere loss in naïve T cells in the first 21 
months in the interferon-alpha group. Telomere losses were similar in both groups during 
the final two years. Expansion of CD8+CD45RA+CD57+ memory T cells and an inverse 
correlation of alanine aminotransferase levels with naïve CD8+ T cell telomere loss were 
observed in the control group but not in the interferon-alpha group. Telomere length at 
baseline inversely correlated with hepatitis-C viral load and body mass index. 
The implications of our findings on the maintenance of T cell replicative capacity, both 
naïve and memory, are explored further in Chapter VI. 
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CHAPTER VI 
 
DISCUSSION 
 
 How memory T cells are maintained in our bodies for decades is a puzzle that has 
long intrigued immunologists. The focus of this work was to understand the maintenance 
of T cell memory through the analysis of T cell telomere length (TL) dynamics. We used 
samples from two cohorts in this research to address our aims: 1) PBMC obtained during 
sustained IFN treatment in individuals with chronic HCV infection, and 2) PBMC 
obtained from healthy donors with memory T cells specific for common viral infections, 
CMV, VZV, IAV, and VACV.  These viruses were selected to reflect diverse patterns of 
viral exposure, including a single acute infection (VACV), recurrent acute infections 
(IAV), viral latency with in-frequent reactivation (VZV), and viral latency with frequent 
reactivation (CMV) (41, 43, 47, 69, 94). In contrast, IFN treatment was an experimental 
model that could reflect the “bystander” effects on T cells that would be seen during 
acute infections with unrelated viruses (60, 61). 
We first had to develop the appropriate experimental tools to measure TL in T cell 
populations of interest. We initially followed published methods for flowFISH analysis  
(140); however, several modifications were necessary in order to make this approach 
suitable for our studies, which included a fixation-permeabilization protocol for RNA 
nuclease treatment.  
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 Using this flowFISH assay, we first analyzed TL in serial PBMC samples from 
chronic HCV (cHCV) patients receiving IFN-alpha therapy and a control group that did 
not receive IFN-alpha. These experiments were performed to understand how TL in T 
cells was affected by type I IFN. The studies permitted us to associate effects on TL with 
both exogenous IFN as well as cHCV itself (Chapter V). Lastly, using flowFISH in 
combination with BrdU labeling to detect virus-specific T cells, we performed a novel 
study on PBMC from ten healthy adults. We compared TL in CD4+ T cells that 
proliferated to viruses with different patterns of exposure to understand the maintenance 
of TL in memory T cells. These studies revealed an unappreciated heterogeneity in the 
distribution of TL in polyclonal T cell populations, as well as unexpected relationships 
between T cell TL and the frequency and pattern of viral re-exposure (Chapter IV). While 
the previous chapters document these findings, the present chapter attempts to interpret 
and evaluate them in a wider context. Finally, models for virus-specific TL dynamics 
during aging and its relationship to the maintenance of T cell memory are presented. 
 
A. Insights from the flowFISH experimental approach along with recent findings on 
telomere biology in highly activated, proliferating T cells 
 We measured TL in T cells that proliferated in vitro to viral antigens using a 
novel combination of the BrdU proliferation assay with a modified flow-FISH TL assay. 
Under these conditions of activation-induced proliferation, highly proliferative T cells 
strongly up-regulate telomerase (79, 95). In light of these telomere dynamics of T cells, 
TL changes during in vitro culture needed to be examined in order to understand how the 
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observed lengths evolved. Initially, we performed experiments to optimize parameters for 
fixation-permeabilization and RNA nuclease treatment to produce a TL measurement in 
agreement with Southern blot TRF results. 
  
 i. Understanding the inflated telomere signal in un-modified flowFISH 
 TL measured by flowFISH in in vitro-stimulated T cells was initially found to be 
significantly higher than TL measured by Southern blot TRF; only when steps were 
added for fixation-permeabilization and RNA nuclease treatment did we find good 
agreement between these assays. These steps were included after the presence of 
telomeric RNA in lymphocytes was reported by others in late-2007 (124, 125). This 
reported discovery and our realization that telomeric RNA could provide non-DNA 
binding targets for our telomere probe prompted us to begin experiments to remove this 
signal component. Very recently work by Picket, et al. demonstrated that high levels of 
telomerase in T cell blasts result in elongated telomeres at day 3. However, in their data 
by day 6 of culture, TLs returned to more normal lengths by a process they termed 
“telomere trimming” (131). Picket, et al. showed that trimming of elongated telomeres 
resulted in the formation of extrachromosomal telomeric circles (T-circles), likely by 
homologous recombination using a Rad51C/XRCC3-dependent mechanism. The T-
circles are closed circles of telomeric DNA, which would present binding sites for the 
telomere probe under the standard flowFISH assay conditions. These extrachromosomal 
T-circles are one likely candidate source for the “inflated” telomere signals we observed 
in the un-modified flowFISH assay (no fixation-permeabilization, Fig 3.1) that fixation-
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permeabilization alone corrected. Inclusion of a permeabilization step in our modified 
flowFISH assay could have allowed un-tethered T circles to diffuse out of the cell and be 
diluted away during the multiple wash steps prior to hybridization. Although this 
mechanism had not been reported at the time we performed these experiments, that work 
now provides an explanation as to how fixation-permeabilization alone could have 
reduced the telomere probe signal in our flowFISH, bringing it closer in line with the 
TRF Southern blot results. The additional removal of telomeric RNA by the RNA 
nuclease treatment further corrected the flowFISH TL signal to bring it into agreement 
with the Southern blot TRF-derived TL (Chapter III, Figure 3.1).  
  
 ii. T cell telomere length changes during activation-induced proliferation 
 The findings of Picket et al. offer a fundamentally altered view of the early 
increase and later decrease, i.e. trimming, in telomere probe florescence in proliferating, 
activated normal T cells (131). Our interpretations of the flowFISH data during in vitro 
proliferation (Chapter IV, Figure 4.1) are also supported and more fully understood by 
this telomere trimming-T circle paradigm. The loss of mean TL in the BrdU+ cells of 
Figure 4.1 between day 5 and day 6 of in vitro proliferation was greater than could be 
explained by the amount of observed proliferation between these time points. Telomere 
trimming provides an explanation for this problem. At day 7, we found the predominance 
of a near normal distribution of TLs in the virus-specific proliferating (BrdU+) T cells. 
Based on the day 6 where the elongated telomere signal was absent, Picket et al 
concluded that trimming to create T circles occurred between days 3 and day 6 in vitro. 
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Based on the Picket, et al. conclusions and our data, we conclude that we are likely 
measuring the remaining true chromosomal TL at day 7. Our observation that in vitro 
proliferation did not correlate with the observed day 7 telomere lengths (Chapter IV, 
figure 4.3.E) strengthens the argument that the telomere lengths measured at day 7 are not 
merely artifacts of in vitro culture. From these lines of evidence, we conclude that the 
differences in TL between virus-specific T cell populations at day 7 reflect true 
differences in telomere length in virus-specific memory T cells at the time of blood 
collection. 
  
B. CMV-specific and VACV-specific CD4+ T cells have higher mean telomere length 
than IAV-specific CD4+ T cells  
 Our finding that TL in CD4+ T cells specific for the non-recurring acute virus 
infection, VACV, was longer than TL in T cells specific for acute but recurring IAV 
supports our initial hypothesis. We had also predicted that TL in CMV-specific T cells 
would be shorter than TL in T cells specific for acute virus infections. Counter to our 
prediction for CMV, we found that TL in CMV-specific CD4+ T cells with high 
replicative capacity was longer than TL in IAV-specific CD4+ T cells. There are likely 
several explanations for these observations. We did not survey an older (aged >60 years) 
adult cohort where clonal expansions of CMV-specific T cells with short TL are most 
prominent (66). Importantly, as described by others, CMV-specific CD4+ T cells may be 
continuously driven to replicative exhaustion in vivo (107); therefore, it is possible that 
findings in an older population would more closely follow our original hypothesis. 
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Another possible explanation for our results is that the experimental approach used 
limited the measurement of TL to T cells that proliferated in vitro in response to viral 
antigen stimulation. Thus our results, showing lower frequency (figure 4.3) and longer 
TL in CMV-specific CD4+ T cells are consistent with the possibility that the cells 
captured in our proliferation assay are T cells more recently recruited from the naive 
repertoire with correspondingly longer telomeres, whereas circulating T cells with short 
telomeres that were unable to proliferate in vitro would not have contributed to the TL 
measurement.  
 
C. Combined longitudinal and cross-sectional modeling enhances the study of virus-
specific memory T cell telomere kinetics in aging populations 
 Our longitudinal modeling, although based on a small cohort of five healthy 
donors, offers some insights into the kinetics of TL of differing virus-specific T cell 
populations. This model indicates that TL differences between virus-specific T cell 
populations may be greater at younger ages and diminish as we age. This would suggest 
that follow-on studies using this proliferative assay approach of an older age cohort (> 60 
years) may not observe significant differences in virus-specific memory T cell 
populations, or that it would necessitate many more subjects in an aged cohort to reach 
statistically significant conclusions. This could be an important consideration in the 
selection and sizing of age cohorts in studies designed to explore differences in memory 
T cell TL differences to a range of viruses or vaccine formulations in age stratified 
populations. The data further suggest caution in interpreting TL kinetics derived from 
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purely cross-sectional data, because survivorship bias, where study participants with short 
telomeres die earlier (141), would lead to an underestimation of age-related TL loss in 
purely cross-sectional data.  
 Interestingly, this hybrid longitudinal/cross-sectional model suggests that 
declining naïve T cell TL with age will have an impact on the control of CMV 
reactivation. If existing memory T cells are continually driven to replicative exhaustion 
(107), new recruitment from naïve T cells would be necessary for CMV-specific T cells 
to maintain control of viral replication. Thus our finding here of relatively long telomeres 
in the CMV-specific CD4+ memory T cells, rather than the short telomeres we predicted, 
could be explained in that 1) all our donors were under age 60, 2) our assay only captures 
T cells with a high proliferative capacity, and/or 3) these may be more recently activated 
from the naïve repertoire and had not yet lost significant TL. 
 
D. VZV reactivation re-established VZV-specific long telomere CD45+ T cells 
 Our observations that TL increased by more than 50% in both VZV-specific 
CD4+ and CD8+ cells in one subject after virus reactivation in vivo have interesting 
implications both for basic lymphocyte biology and use of VZV vaccine for secondary 
prophylaxis (boosting at an older age). There are at least two models to explain this 
increase in TL in VZV-specific T cells: elongation of shortened telomeres in pre-existing 
memory T cells, or recruitment of new naïve T cells (with longer TL) into memory. 
Human T cells undergoing activation-induced proliferation have been shown to up-
regulate telomerase, which has been proposed to maintain TL, but in general does not 
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lead to significant telomere elongation in lymphocytes (84). On the other hand, the 
recruitment of new naïve VZV-specific T cells with longer TL better explains this TL 
increase and is the explanation that best fits our data based on our current understandings 
of T cell biology. With regard to VZV prophylactic boosting, this interpretation would 
recommend re-vaccination before the age-related decline in naïve T cell TL compromises 
the recruitment and formation of new long-lived memory T cells. 
 The lack of a significant population of cells with long TL in CD45RA+ VZV-
specific CD4+ T cells in the blood sample collected prior to VZV reactivation (Figure 
4.8.F) provides an intriguing opportunity for the study of T cell-mediated control of 
latent-reactivating herpesviruses using the imprint that reactivation may leave on its 
virus-specific memory T cell TLs. Our findings support a model where a gradual loss of 
TL in a long-lived reserve of memory T cells would lead to a loss of in vivo effector T 
cell replicative capacity and a waning frequency of effector T cells, finally becoming 
insufficient in quantity and quality to suppress reactivation (142). The clinically evident 
reactivation with replicating virus in turn would drive a strong immune response, 
including the recruitment of additional naive T cells.  
  
E.  Accelerated T cell TL loss under sustained IFN therapy 
The study of subjects from the HALT-C trial (Chapter V) indicated that sustained 
peg-IFNα therapy (90 μg/week) was associated with an increased rate of TL loss in both 
naïve CD4+ and CD8+ T cell subsets. Additionally, based on a single intermediate time-
point, the enhanced TL loss related to IFNα therapy was fully concentrated in the initial 
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21 months of the trial. The delineation of TL changes in T cell CD45RA+/-/CD57- subsets 
showed that declines in T cell TL did not represent shifts between naïve (long TL) versus 
memory (shortened TL) T cell proportions, but true decreases in TL with the greatest 
impact on the naïve T cell subsets. The lack of an accelerated TL loss in naïve T cells in 
the second interval in the peg-IFNα group suggests that a new homeostasis was reached. 
These findings are consistent with the telomere erosion effects of increased lymphocyte 
turn-over in response to a sustained lymphopenic signal as predicted from the 
mathematical models of de Boer and Noest (143). Increased T cell turn-over would also 
account for our observation that sustained peg-IFNα treatment inhibited the expansion of 
CD8+ CD45RA+ CD57+ TEMRA cells, a phenomenon that was observed in the control 
group. 
Based on the design of the HALT-C trial, subjects in both groups received 
combination therapy with peg-IFNα (180 μg/week) plus ribavirin for the initial 24 weeks 
of the study (113). PBMC were not available from other intermediate time points. 
Therefore, it is possible that accelerated TL loss occurred in both groups during the initial 
phase of lead-in therapy. Average TL could then have rebounded in the control group 
between the end of therapy at week 24 and month 21, whereas ongoing, lower-dose peg-
IFNα therapy maintained the lower average TL (or suppressed a TL recovery) in the 
therapy group. Consistent with this interpretation, the decline in TL was slower during 
the second interval than in the earlier interval in the therapy group. If this interpretation is 
correct, it is impossible to determine whether the effect of the initial therapy on TL is 
attributable to the higher dose of peg-IFNα or to ribavirin. Nevertheless, sustained peg-
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IFNα was clearly associated with accelerated TL loss during the subsequent 3½ years in 
comparison with the control group. 
 
F. Baseline TL correlates with viremia and obesity in cHCV subjects 
An important finding from the interferon study was the correlation of baseline T 
cell TL in cHCV subjects with viremia and BMI. It should be noted that subjects in the 
randomization phase of the trial had endured HCV viremia for decades (range: 14-51 
years) and failed to achieve SVR during combination peg-IFNα-ribavirin therapy. The 
absence of a negative correlation of baseline T cell TL with age in this cohort may 
therefore reflect stronger impacts of long-term viremia and the generally high levels of 
obesity in these subjects. 
We speculated that the inverse association between serum viral RNA levels and 
baseline TL may reflect chronic elevated T cell activation, cell death, and proliferation 
due to persistent presentation of HCV antigens in a dose-dependent manner (58). 
Alternatively, higher circulating viral RNA levels may also drive greater endogenous 
type I IFN production. A negative correlation of BMI with baseline TL in naïve T cells 
could also reflect chronic inflammation in obesity (144). Chronic inflammation as a result 
of obesity may lead to decreased thymic output (145), inducing increased homeostatic 
proliferation of naïve T lymphocytes and thus a decrease in TL through replicative 
erosion. 
Another possible explanation for the lack of an age-dependent TL association in 
this cohort relates to evidence that short telomeres play a causal role in a variety of age-
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related diseases (146-149). The HALT-C study inclusion criteria limited enrollment to 
cHCV without other co-morbidities, such as a history of cardiovascular disease, 
neoplasia, or other chronic condition which might have prevented a subject from 
competing the 4 year long trial (113). Thus it is plausible that the study inclusion criteria 
biased the enrolled study population away from subjects with very short telomeres. 
 
G. Serum transaminases as indicators of hepatocyte killing and loss of naive T cell 
TL 
 Elevated ALT and AST levels in cHCV are indicative of hepatocellular 
inflammation and necrosis (150). Our finding of a correlation of serum ALT and AST 
levels with naïve T cell TL loss in the control group possibly reflects T cell responses to 
infected HCV-infected hepatocytes and the extended time frame over which telomere 
lengths were analyzed. This relationship was possibly obscured in the peg-IFNα group by 
the effects of continuous therapy. The correlation between TL changes and ALT/AST, 
which could be due to T cell clonal exhaustion, immuno-senescence, or a combination of 
these and/or other immunological factors (151, 152), suggests that normalization of liver 
enzyme levels in the blood may coincide with a reduction in T cell turn-over and thus 
reduced telomere erosion. 
 
H. Telomerase inhibition was not seen with interferon therapy   
We hypothesized that maintenance peg-IFNα therapy would cause increased TL 
loss in T cells as a result of inhibition of telomerase activity (82, 86). However, we did 
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not find a significant difference between the peg-IFNα and control groups in telomerase 
activity in PBMC stimulated in vitro. It is possible that, using in vitro-stimulated PBMC, 
the telomerase assay failed to detect an inhibitory effect of peg-IFNα therapy that existed 
in vivo. In any case, as naive T cells do not express telomerase and are antigen 
inexperienced and thus have not gone through a telomerase-inducing clonal expansion, a 
telomerase inhibition mechanism falls short in explaining the predominance of an 
accelerated TL loss on naïve T cells. Further in these older adults where thymic output of 
new, longer telomere naïve T cells may be negligible, a reduced thymopoesis explanation 
is also not a likely source of TL loss in the naïve T cell compartment. Taken together, our 
data suggest a telomerase inhibition mechanism by IFN does not explain the accelerated 
TL erosion in the naïve T cell compartment. 
 
I. Interferon-induced TL loss may reveal a hierarchy of onset of T cell subset 
senescence 
We found a decline in the effect of peg-IFNα on TL loss with increasing age. 
Increasing age is associated with increased failure rates of IFN therapy for cHCV (55). 
This may suggest that elevated TL erosion caused by peg-IFNα is counteracted by 
replicative senescence occurring at different rates within different T cell compartments. 
The results of the analysis of IFNα-induced TL loss in CD4+ and CD8+ T cell subsets in 
the different age groups suggest a hierarchy of age-dependent T cell senescence in 
chronic HCV patients, occurring in the order: memory CD4+ > memory CD8+ > naïve 
CD4+ > naïve CD8+. This result and our conclusion are consistent with the finding by 
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Hoare, et al. that TL in CD4+ CD45RO+ memory T cells was a stronger predictor of SVR 
with IFN therapy than TL in any other T cell subset (153). Refractoriness to TL loss in 
memory CD4+ T cells under the influence of type I interferon stimulation (as seen in the 
older age group in our study) may signal the onset of immunosenescence that affects the 
clearance of virus from a chronic infection state. 
 
J. Strengths and Limitations of the Studies 
 Several additional points are worth noting regarding the methodological approach 
described in this thesis. An inherent limitation of flow-FISH is the limited number of 
cellular phenotype markers that survive the hybridization conditions (119). A further 
limitation of our approach to study virus-specific T cells using BrdU staining is the 
measurement of TL only in cells that proliferated in vitro.  Therefore we were not able to 
perform a robust cross-sectional analysis of TL in CD8+ T cells with the experimental 
conditions we used. 
On the other hand, metrics of TL distribution such as median TL or skewness, 
which can be derived from single cell methods such as flow-FISH, may be quite 
informative to understanding long-lived T cell memory. TL distribution parameters of 
single cells are not captured in Southern blotting and PCR-based methods of TL 
measurement (109). Using the additional information available from flow cytometry, we 
identified a subset of BrdU+ cells with long TL that were CD45RA+ and CD27+. The 
long TL in these cells could be advantageous in maintaining long-term immunologic 
memory, but further studies would be needed to confirm such a role.  
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K. Virus-specific memory T cell study: Summary, Implications, Models 
 We hypothesized that virus-specific memory T cells that proliferate to acute, non 
recurring infections have longer telomere lengths than T cells that proliferate to recurring 
or reactivating viral infections. In line with our hypothesis, we found that TLs in VACV-
specific CD4+ T cells were longer than TLs in IAV-specific CD4+ T cells. Since re-
exposure to VACV is not likely, there would be fewer opportunities for activation-
induced erosion or accelerated depletion of memory T cells. In contrast, yearly re-
exposure to IAV could slowly erode the proliferative reserve of memory T cells while 
maintaining elevated circulating frequencies of effector memory, leading to the shorter 
telomeres and higher BrdU+ frequencies observed in IAV-specific CD4+ T cells. Longer 
TL in CMV-specific CD4+ T cells and the data from others that CMV reactivation may 
continuously drive T cells to replicative exhaustion (107) would imply that regular 
recruitment of naive T cells would be needed to sustain viral control from reactivation. A 
proposed model of maintenance of CMV-specific CD4+ T cells against the backdrop of 
age-related declining naïve T cell TL and its impact on host T cell immunity is presented 
in Figure 6.1. The longer telomeres of the CMV-specific CD4+ T cells that proliferate in 
conjunction with the lower slope of TL loss in this population relative to that of naïve T 
cells predicts that the TL of CMV-specific CD4+ T cells will intersect with the TL of 
naïve T cells 20 years earlier than for the other three viruses studied. This could have 
significant implications for host T cell maintenance. 
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  This data-derived model provides a possible explanation of the CMV-specific T 
cell functional defects seen in the elderly, as observed by others (71, 154-156). These 
functional defects have been described as clonal expansions of CMV-reactive CD8+ T 
cells which are apoptosis resistant, but lack many anti-viral functional characteristics 
such as robust interferon-gamma secretion. An explanation of these CMV-reactive CD8+ 
memory T cell functional defects may lie in TL limitation of proliferative capacity in the 
naïve T cell compartment. A truncated proliferation program due to the Hayflick limit 
could translate to an inadequately completed differentiation program with the observed 
result being the described dysfunctional memory T cell. As the TL of the naïve T cell 
compartment further declines with advancing age, the proliferative response becomes 
progressively more truncated by this unyielding Hayflick limit. In this scenario the 
inability of dysfunctional effector T cells to fully restrain CMV replication would lead to 
heightened innate inflammatory cytokine signaling such as IL-6, TNF, or type I IFNs. 
This sustained chronic low level inflammation would lead to non-specific bystander 
effects to all circulating T cells in a self-reinforcing feedback loop as proposed by others 
(156-158). 
Additional longitudinal studies of T cell TL dynamics in a larger number of 
healthy individuals are clearly needed, both to validate these preliminary models of 
memory maintenance, and to further extend the data set to older subjects. Longitudinal 
studies of TL in HIV-, HBV-, and HCV-specific T cells would shed light on the 
relationship between exhaustion of virus-specific T cell memory and declining TL in 
virus-specific and naïve T cells, against the backdrop of age-related T cell senescence 
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(66, 154, 156, 158-161). The visualization of TL distribution in an ensemble of individual 
virus-specific T cells, made possible with flow cytometry, may provide clearer insights to 
the factors affecting the generation of T cell memory replicative capacity to different 
pathogens and vaccines. 
Additionally, we consistently noted a small fraction of long telomere CD45RA+ T 
cells that arose in each of the four virus-specific responses tested for all ten donors. The 
CD45RA- fraction, in contrast, consisted of cells with shorter telomeres and lower levels 
of CD27 -- both characteristics of effector memory T cells. Recently published work by 
others have provided support for the presence of highly proliferative CD45RA+ memory 
T cells with limited differentiation in humans (11). Our data here provide insight of how 
human T cells, with different functional fates arising during activation and expansion, can 
provide both the differentiated effector CD62L- CD45RA- responses needed for antiviral 
effects, while simultaneously establishing a smaller pool of long telomere CD45RA+ T 
cells with high replicative potential. These ideas of long telomere T cell generation 
during an acute viral response are embodied in the proposed models shown in Figure 6.2.  
During the response to primary (1o) viremia, T cell recruitment and activation 
produces a large population of virus-specific T cells. The differentiation status of these 
virus-specific T cells rapidly increases during activation and expansion, leading to 
shortened telomere lengths in the large effector population. Once viremia resolves, T cell 
numbers dramatically contract, as most are short lived, highly differentiated effectors and 
undergo apoptosis.  
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Over periods of years to decades, the total number of circulating effectors slowly 
declines during homeostatic maintenance as long-lived T cells slowly consume their 
telomere length to support homeostatic maintenance.This small population of 
CD45RAhigh T cells with long telomeres, established during activation-dependent 
induction of memory, maintains the circulating effector memory population through slow 
homeostatic proliferation to maintain a small but steady level of circulating virus-specific 
T cells that have immediate effector function if stimulated by their cognate antigen via 
TCR stimulation. Sustained memory maintenance during homeostatic proliferation leads 
to slow, but steady telomere loss. Re-infection or reactivation leads to antigen-driven 
activation, clonal proliferation, and increased differentiation. Large scale recruitment of 
memory T cells leads to a diminished telomere length within the long-lived, long 
telomere CD45RA+ T cell memory.  
As speculation, telomere maintenance related to high telomerase expression 
combined with a suppression (or avoidance) of homologous recombination-dependent 
telomere trimming (131) during activation-induced memory induction could create small 
number of CD45RA+ memory with long telomeres. As we found with the VZV-specific 
response shown in Figure 4.8, the characteristic long-telomere CD45RA+ CD4+ T cell 
reserve was not observed prior to VZV-reactivation in this donor. Others have shown that 
VZV-reactivation occurs when circulating VZV-specific T cells falls below critical levels 
(69, 70, 162). This strong reactivation likely led to recruitment of new VZV-specific T 
cells from the naïve repertoire with long telomeres and high proliferative capacity, 
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restored VZV T cell-mediated control, and replenished the long telomere CD45RA+ 
CD4+ T cell population. 
During homeostatic maintenance of T cell memory, the replicative capacity 
contained within a single CD4+ CD45RAhigh long telomere memory T cell supports 
maintenance of a large number of differentiated clonal daughter cells. Daughter cells 
differentiate to establish more differentiated effector functions following programmed 
fates (Th1, Th2, Tfh, etc.) as they proliferate. Differentiation and division simultaneously 
induces telomere erosion. Early differentiated T cells maintain poly-functional responses 
and the capacity for proliferation and IL-2 secretion, while more differentiated daughter 
cells have shorter telomeres and limited replicative capacity.  
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Figure 6.2 (continued from previous page) 
 
(A) In response to primary (1o) virus infection (red line), a large population of antigen-
specific T cells (blue line, upper graph) become activated during the acute phase. During 
activation and expansion of these virus-specific T cells (shaded area I, lower graph), a the 
majority differentiate to shorter lived-effectors and their average telomere lengths decline 
(thick blue line). Once viremia resolves, T cell numbers dramatically contract. Unknown 
mechanisms or pathways during the periods of activation-induced memory induction 
create a small population of CD45RAhigh T cells with long telomeres (blue dashed line, 
lower graph). During homeostatic proliferation (green lines in area II), some CD45RA+ T 
cells with long telomeres steadily produce daughter cells to maintain a population of 
more numerous shorter-lived, more differentiated effector memory cells. Re-infection or 
reactivation (second shaded area I) can also lead to loss of telomere length within the 
long-lived, long telomere CD45RA T cell population as clonal expansion results in large 
clonal burst of differentiated, short lived effectors being produced. Renewal and 
maintenance of the long telomere T cell memory may increasingly become compromised 
due to increasing telomerase repression after several rounds of clonal activation. Once the 
long-telomere T cell reserve is depleted, recruitment of new clones from the naïve 
repertoire, with long telomeres and high proliferative capacity, would then be needed for 
host protection. 
(B) The enhanced replicative capacity contained within a single CD4+ CD45RAhigh long 
telomere memory T cell supports homeostatic maintenance of an army of more 
differentiated clonal daughter cells (area II in A above). Telomere lengths in all cells 
would slowly decline due to replication-dependent telomere erosion as telomerase 
expression is low to non-existent during homeostatic proliferation. Daughter cells 
become more differentiated with effector functions following programmed fates as they 
proliferate. Early differentiated T cells maintain poly-functional responses and 
proliferative capacity and IL-2 secretion, while fully differentiated daughter cells have 
shorter telomeres and limited replicative capacity. 
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L. Interferon therapy telomere length study: Summary, Implications, Model 
 
From the HALT-C study we found data to support the hypothesis that sustained 
IFN therapy enhanced loss of telomere length. However, we found no data to support 
telomerase inhibition as a mechanism for this effect. Instead, the data showed TL loss 
was concentrated in naïve T cells, and a steady CD8+ CD57+ TEMRA expansion occurred 
in the control group and not in the therapy group which implies that IFN suppressed these 
memory expansions in the therapy group. These data, along with the known ability of 
IFN to cause lymphopenia, led us to conclude that greater homeostatic proliferation, 
resulting in elevated TL erosion, was a likely mechanism that best fit our data.   
Enhanced naïve T cell TL loss in cHCV subjects who received long-term peg-
IFNα therapy suggests that T cells in these subjects have reduced proliferative reserve. 
Subjects receiving type I IFN therapy are known to be more susceptible to bacterial 
infections; this has been attributed to neutropenia, but several studies have shown no 
temporal correlation between neutrophil count and infections (163, 164). Diminished 
memory T cells and proliferative reserve related to naïve T cell TL loss, as shown in this 
study, could contribute to the increased susceptibility to infection and disease while on 
IFN therapy. Importantly, diminished naive T cell proliferative TL reserve incurred under 
sustained IFN therapy may persist well beyond the end of therapy. Indeed, as age-related 
thymic involution severely limits the production of new, long-telomere, naïve T cells 
(153), a sustained accelerated TL erosion may leave a permanently degraded naïve T cell 
compartment. Support for this possibility comes from a recent analysis of a subset of 
patients from the HALT-C cohort prospectively followed for more than 5 years after the 
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trial. That study showed that rates of non-liver-related death were significantly higher 
(p=0.01) among patients with liver fibrosis who received the 3½ year peg-IFNα therapy 
compared to similar patients in the control arm (165). A model of the effects of an 
accelerated naïve T cell TL loss that may explain this increased mortality is proposed in 
Figure 6.3. Accelerated telomere loss in the naïve T cell compartment would result in 
earlier impacts on the ability to maintain T cell responses to recurring infections due to a 
diminished naive T cell proliferative potential. Accelerated onset of memory T cell 
immunosenescence thus would compromise T cell mediated immunity at an earlier age, 
providing the explanation for the increased mortality seen in the HALT-C long-term 
interferon therapy patients. 
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M. Conclusions 
 These studies of T cell telomere lengths extend prevailing models of the 
formation and maintenance of T cell memory with insights on long telomere T cells, and 
open up novel approaches for further study. In the process of this thesis research, several 
of the initial hypotheses were ultimately supported by the data (e.g. VACV-specific TLs 
were longer than IAV-specific TL and IFN accelerated TL loss) and others refuted 
(CMV-specific TL were longer than IAV-specific TL). The complexity of this picture of 
T cell telomere length dynamics against the background of age-related decline in TL 
suggests that re-vaccinations such as for VZV should be undertaken before the onset of 
naïve T cell senescence for greatest efficacy. Further it suggests that efforts to slow or 
prevent excessive TL loss in the naïve T cell compartment may be vital for healthy 
longevity. Importantly, the telomere length assay methods used here may enable future 
studies using T cell telomere dynamics as a “reporter” for understanding the kinetics of 
viral reactivation from latency, which are not easily quantifiable in otherwise healthy 
individuals.  
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